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Introduction 
In the differential diagnosis of men with erectile dysfunction (ED) it is important to know 
whether or not the male patient is potentially sexually potent, i.e. whether or not a (semi) rigid 
erection, presumably sufficient for intercourse, can occur (e.g. I). Preferably such information 
is gathered by a thorough history taking, and, if necessary, followed by non-invasive 
investigations. Penile erection is the result of a neurovascular response to a complex set of 
visual, tactile and psychogenic stimuli (2). It is thought to result from increased arterial flow 
through the cavernous vessels "With subsequent sinusoidal engorgement and decreased venous 
return. Anatomic innervation is derived from both sympathetic and parasympathetic chains at 
the posterolateral surface of the prostate (2). 
Several years ago, long before the introduction of sildenafil (Viagra®), we started to use 
visual sexual stimulation (VSS) and vibrotactile stimulation (VIE) (see Appendix), to be 
followed, at a later stage by intracavernosal injection (leI) in routinely screening men with 
ED (3). It was thought to be necessary to differentiate between somatic and psychogenic ED; 
moreover, it was believed that the physiological responses had some therapeutic properties in 
itself (4). Nowadays we find it sufficient to take a good sexual history, preferably using a 
validated structured questionnaire. To that end we have developed a IS-item questionnaire 
regarding various aspects of sexual functioning over the past four weeks, adapted at the 
circumstances of different patient's categories. This questionnaire gives detailed information 
about patient's sexual (dys)functioning. 
Loosing a testicle can result in a change of body image and difficulties in sexual functioning 
(e.g. 5,6,7). Patients should be counseled in sexual and intimate matters and the possibility to 
receive a testicular prosthesis should be offered. Cosmetic appearance after implantation is 
satisfactory, although not perfect. Unfortunately it seems that the possibility of having a 
testicular implant is not always routinely discussed with the patient, e.g. some time before the 
moment of castration for testicular cancer. We thought it worthwhile to study sexual 
functioning in a group of patients who had received a testis prosthesis. 
External beam radiotherapy (ERr) for benign diseases is gaining its popularity in spite of 
the fear of secondary malignancies, but it still has its place in specific diseases. Peyronie's 
disease (PD) has been claimed to be successfully treated with ERr (8,9), but sexual 
functioning in patients with PD following ERr has never been thoroughly assessed. 
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We have undertaken such a study in 106 PD-patients treated with ERT in our hospital over 
the last 15 years. 
QUality of Life in cancer patients has recently become very important (10,11). Current trials 
pay in general more attention to matters related to well-being and life expectations after 
cancer treatment (12). Unfortunately, sexual functioning is not always well investigated. 
There still seems to be difficulties in facing the subject of "sex~' in cancer patients. Doctors 
are reluctant to discuss sexual matters and they are usually focussed on long survival. Patients 
are nowadays more aware of such matters and they are more keen to make their own choices 
among the various treatment modalities (13). Sexual dysfunction after radiation for prostate 
cancer is becoming a concern, even more so because of the increasing number of screening 
programs and prostate specific antigen testing, which results in a higher incidence of younger 
patients diagnosed with prostate cancer. It is still debatable whether early detection and 
treatment of prostate cancer by either radical surgery or radiation therapy will result in longer 
overall survival (14). It remains for a fact, however, that patients undergoing radical surgery 
are usually younger and with less comorbidity than patients undergoing ERT (15), therefore 
sexual functioning in patients undergoing surgery is often better than in patients receiving 
ERT. 
The impact of the treatment (either surgery or radiotherapy) on potency can only be 
determined if a baseline, pretreatment assessment of erectile function is included (16). It has 
been suggested that high percentages (up to 60%) of the patients may be impotent already 
before radiation treatment (17). Therefore, there is a need of baseline, pretreatment data. TIlls 
prompted us to study sexuality in a group of prostate cancer patients awaiting treatment. 
Many papers have been published dealing with ED after radiation for prostate cancer, with 
an enormous variety in the methodology used for ED evaluation. Different definitions of 
potency/impotence have been used; moreover, time of ED evaluation since treatment is often 
not indicated. Because of these differences and the great variability in the literature there is a 
need of an up to-date overview to critically analyze the -sometimes contrasting- findings in 
the literature regarding sexual functioning after radiation therspy for prostate cancer. Thus, in 
the final chapter of this thesis a review of the existing literature on sexuality following 
radiation therapy for prostate cancer is presented. 
Introduction 13 
References 
I. Slob AK, Blom JHM, van der Werfften Bosch JJ. Erection problems in medical practice: 
differential diagnosis with relatively simple method. J UroI1990;43:46-50. 
2. Mebnan A and Gingell Je. The epidemiology and pathophysiology of erectile 
dysfunction. J UroI1999;161:5-11. 
3. Slob AK, Steyvers CL, Lottman PEM, van der Werff ten Bosch JJ. Routine 
psychophysiological screening of 384 men with erectile dysfunction. J Sex & Marital 
Therapy 1998;24:273-279. 
4. Slob AK and van der Werff ten Bosch JJ. Psychophysiological diagnostic research in 
males: 10 years of experience. ScandJ Se:xoI1999;2:13-20. 
5. Van Basten JP A, Jonker-Pool G, van Driel MF, Sleijfer DT, van de Wiel HEM, Mensink 
HIA, Schraffordt Koops H, Hoekstra HI. Fantasies and facts of the testes. Br J Urol 
1996;78:756-762. 
6. Tinkler SD, Howard GCW, Kerr GR. Sexual morbidity following radiotherapy for germ 
cell tumors of the testis. Radiother OncoI1992;25:207-212. 
7. Arai Y, Kawakita M, Hida S, Terachi T, Osaka Y, Yoshida O. Psychosocial aspects in 
long-term survivors oftesticular cancer. J UroI1996;155:574-578. 
8. Rodrignes cr, Njo KH, Karim ABMF. Results of radiotherapy and vitamin E in the 
treatment ofPeyronie's disease. Int J Radiat Oncol Bioi Phys 1995;31 :571-576. 
9. Viljoen 1M, Goedhals L, Doman MI. Peyronie's disease-a perspective on the disease and 
the long-term results of radiotherapy. South Afr Med J 1993;83:19-20. 
10. Ofinan US. Sexual quality of life in men with prostate cancer. Cancer 1995;75:1949-
1953. 
11. Schover LR. Sexual rehabilitation after treatment for prostate cancer. Cancer 
1993;71:1 024-1 030. 
12. De Haes J, Curran D, Young T, Bottomley A, F1echtner H, Aaronson N, B1azeby J, et al. 
Quality of life evaluation in oncological trials-the EORTC model. Eur J Cancer 
2000;36:821-825. 
13. Singer PA, Tasch ES, Stocking C, Rubin S, Siegler M, Weichse1baum R. Sex or survival: 
trade-offs between quality and quantity of life. J CZin OncoI1991;9:328-334. 
14 Introduction 
14. Labrie F, Candas B, Dupont A, Cusan L, Gomez JL, Suburu RE, Diamond P, et al. 
Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospectieve 
randomized controlled trial. Prostate 1999;38:83-91. 
15. McCammon KA, Kolm P, Main B, Schellhammer PF. Comparative Quality-of-Life 
analysis after radical prostatectomy or external beam radiation for localized prostate 
cancer. Urology 1999;54:509-516. 
16. Zinreich ES, Derogatis LR, Herpst J, Auvil G, Piantadosi S, Order SE. Pretreatment 
evaluation of sexual function in patients with adenocarcinoma of the prostate. Int J Radiat 
Oneol Bioi Phys 1990, 19:1001-1004. 
17. Zinreich ES, Derogatis LR, Herpst J, Auvil G, Piantadosi S, Order SE. Pre and 
posttreatment evaluation of sexual function in patients with adenocarcinoma of the 
prostate. Int J Radiat Oneol Bioi Phys 1990;19:729-732. 
Chapter 2 
Visual erotic and vibrotactile stimulation and intra cavernous 
injection in screening men with erectile dysfunction: 
a 3 year experience with 406 cases 
L. Incrocci, W.c.J. Hop and AX. Slob 
Int J Impotence Res 1996;8:227-232 

Chapter 2 17 
Visual erotic and vibrotactile stimulation and intracavernous 
injection in screening men with erectile dysfunction: a 3 year 
experience with 406 cases 
L IncrocciU , WCJ HOpl and AK SIobl 
IDepartment of Endocrinology 5' Reproduction. Faculty of Medicine and Health Sciences, Erasmus Universily. PO Box 
1738,3000 DR Rotterdam; ZDepartment of Urology, Academic Hospital 'Dijkzigt', Erasmus University Rotterdam; and 
'Department of EpidimioJogy 5' Biostatistics, Erasmus Um'versity Rotterdam 
To establish the number of patients with erectile dysfunction (ED) who appear to be sexually 
potent when exposed to visual erotic (VES) and vibrotnctile stimulation (VIS) and to investigate 
whether or not older patients are less responsive to VESNIB than young patients. 
Retrospective analysis of data on 406 consecutive patients screened for ED with VES, 
VES+ VIB, VES + Intracavernous injection (lCl). 
Partial or full erection was obtained in 34% of patients with VES, 5Z% with VES + VIE. 82% 
with VES+ICL Men<40y (n=86) responded better than men>40; between 40 and 80 no 
differences in penile responses were found. 50% of patients who reported no morning/night 
erections appeared to have good. rigid nocturnal penile tumescence (NPT). 
The use ofVES, VES + VIB, VES + ICI is strongly recommended in the screening ormen with ED 
of aU ages: up to 80% will respond with a good erection. Only a positive penile response has 
diagnostic significance. The positive results reduce the necessity for further invasive investiga-
tions. 
Keywords: erectile dysfunction: visual exotic stimulation; vibrotactilo penile stimulation; 
intracavernous injection: impotence 
Introduction 
In screening patients with erectile dysfunction (ED) 
it is important to know whether or not the man is 
potentially sexually potent. Preferably such infor-
mation is gathered through a thorough history taking 
followed by non-invasive investigations. Since 1988 
we have routinely exposed our patients with ED to 
visual erotic stimulation (VES) while penile circum-
ference and rigidity were measured with an erecti-
ometer.l The latter device was also used for 
nocturnal penile tumescence (NPT) measurements 
when patients were asked to sleep with an erecti-
ometer around the base of the penis for four 
consecutive nights. l Over the years we optimi2:ed 
our VES methodology with concomitant vibrotactile 
stimulation (VIB) to the underside of the top of the 
penis.2-1 When poor or no penile response was 
obtained following VES and VES + VIB. an intraca-
Correspondence: Dr AK Slob. 
Received 27 October 1995: revised 18 June 1996: accepted 16 
July 1996 
vernous injection (lCI) with a vaso-active drug was 
given,s followed by VES.- It should be kept in 
mind that only a positive penile response to VES or 
YES + VIB has diagnostic and possibly therapeutic 
significance.l •G 
We thought it worthwhile to retrospectively study 
the data on all patients who visited our psychophy-
siology laboratory in the years 1991-1993; we 
reported earlier on patients in the preceding years 
1988-1990.°·10 One of the main questions in the 
present study was how many of these men with ED 
were sexually responsive in the laboratory. In other 
words, is it worthwhile to carry out this rather time 
consuming investigation in differential diagnosis of 
men with ED? To what extent is age a significant 
factor in the sexual response? The latter question 
was posed because Buvat and co-workersll had 
indicated that VES seemed useless over the age of 
50, even when it was combined with a low dose lei 
with a vasoactive agent. In the late eighties the lei 
with a vasoactive substance became popular in the 
process of differential diagnosis of ED.12-14 Quite 
recently the combinations of YES and leI was 
advocated. D.l!> A final question dealt with the 
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proportion of psychogenic vs somatogenic origin of 
the ED in our patients. 
Materials and methods 
This paper reports retrospectively on filed data of 
406 consecutive patients with ED who visited our 
outpatient urology clinic and psychophysiological 
laboratory in the years 1991 through 1993, for 
differential diagnosis of their problems. Erectile 
dysfunction can be defined as 'inability to attain 
andlor maintain penile erection sufficient for satis~ 
factory sexual performance'.16 All patients were 
routinely evaluated for relevant hormones and 
underwent a physical examination by the urologist; 
in these years echocolorl doppler studies were not 
routinely carried out. Subjects were orally inter-
viewed regarding their personal. medical and sexual 
history. as well as their sexual functioning and 
problems. They were also asked to fill out a number 
of forms soliciting detailed information on current 
sexual functioning. Questionnaires had been used 
earlier and had appeared to give satisfactory in-
formation. 1 
When past history revealed that patients did not 
experience morning/night erections they were asked 
to sleep for four consecutive nights with an 
erectiometer: two nights with a yellow (requires 
approximately 250 gr expansion force). two nights 
with a green erectiometer (requires about 450 gr 
expansion force). It should be emphasized that the 
erectiometer measures increase in penile circumfer-
ence as well as rigidity.1 Patients were instructed 
how to use the erectiometers and how to register the 
increments. A pre-paid envelope was used to mail 
erectiometers and data to the investigators. The use 
of the erectiometer is not a standard practice 
internationally. although in our clinic and some 
other Dutch clinics it has been used for many years. 
In the psychophysiology laboratory virtually all 
patients were exposed to an erotic video (VES; 
duration approximately 10 min). while penile 
response (that is rom increase in circumference) 
was measured with a yellow erectiometer. Subjec-
tive sexual and genital arousal was filled out on a 
questionnaire after the VES. Depending on the 
sexual orientation of the patient heterosexual or 
homosexual erotic videos were used. 
Our VES methodology was improved by admin-
istering concomitant Vibrotactile stimulation (VIE) 
to the underside of the tip of the penis. 7.~7 The 
minivibrator. attached to a yellow erectiometer. 
weighing approximately 20 g. generates vertical 
and lateral displacement. The output frequency is 
adjustable from 10-60 Hz and the surface area of 
stimulation is approximately 270 mm.2•3 When the 
use of VIE became a routine procedure. this meant 
that patients were exposed to VES twice (two 
different videos), once without and once with VIE. 
This was done because patients virtually never 
responded with a full, rigid erection with VES alone. 
In our patients, when no response occurred, VES 
(a third erotic video) was combined with an leI of 
papaverine sulfate (other vasoactive substances 
were not used in those years). The median dose 
administered was 50mg (mean 52.2±18.7s.d.). A 
lower dose (between 15 and 50mg) was given when 
the patient had earlier responded positively to 
papaverine in the outpatient clinic. and higher 
doses (between 50 and 100mg) when the patient 
had not responded earlier. 
Because the data were not normally distributed, 
and no suitable transformation of data approximated 
a normal distribution. non-parametric statistics were 
applied, namely Kruskal-Wallis test or Mann-
Whitney test for comparisons between groups and 
Wilcoxon's test for comparisons within groups. 
Correlation coefficients given are Speannan's (rn). 
The level of significance was set atP= 0.05 (2 tailed). 
Results 
Social, medical and other parameters 
Mean age of the 406 patients was 50.6 ± 12.5 s.d. 
(median 52; range 19-81). Ethnic background was 
64% (n=258) Dutch white. 11% from Surmamroots 
(n=43), 22% from Turkish. Moroccan and other 
nationalities (n=91). 3% unknown. The vast ma-
jority of men indicated a heterosexual orientation 
(96%, n=389), 3% were homo or bisexual (n=12). 
About one-third of the patients (n = 135) were on 
medication known to possibly affect sexual func-
tioning, namely antihypertensives, antidepressants 
and major tranquillizers. Only 15% (n:::::: 61) had 
undergone some surgery that could be associated 
with erectile difficulties. namely prostatectomy and 
heart or major vascular surgery. Approximately one-
third (n=141; 35%) had a chronic disease assumed 
to be associated with erectile dysfunction. The most 
prevalent diseases were diabetes mellitus (n = 57, 
including those with hypertension). and hyperten-
sion only (n=38). There were 129 (32%) men who 
smoked an average of13 cigarettes per day (range 1-
50 day). 160 (39%) did not smoke, and of 117 it was 
unknown. A total of 264 men consumed alcoholic 
beverages. with a mean of 1.3 glasses/day (range 
0.5-10 day), 87 (21.4%) abstained from alcohol, 
while for 55 (13.5%) it remained unknown. 
Sexual activities 
In Table 1 mean frequencies per month of various 
sexual activities are depicted: morning/night erec-
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Table 1 Sc=al 3ctivities (frequencies per month: mean±s.d.) and sexual difficulties (J point semantic scale 1 ""alWllYS. 4 =about 50";;' of the time, 
7 = never, only extremes I and ~ 6 and 7 are presented) Il& reported by the 406 patients 
Sexual aCtivities N Median Mean±s.d. Sexual difficulties Often (1 ±2) Seldom (6±7) 
Morning/night erections 350 2 7.7±10.5 Problems with achieving an crection 49% [n=153) 24% (n=76) 
Spontaneous daytimo eroctions 338 0 1.9±5.6 Problems with mnintaining croctions 78% (n=245) 7% (n=23) 
Sexual activity with partner 351 2 3.9±4.9 Premature ejaculation 32% (n=99) 58% (n=178) 
Mnsturbation 363 0 2.2±5.4 Inability to ejaculate 11% [n=31) 55% [n=166) 
Erotic drolllll 333 0 O.5±lA Foar of failuro 47% [n",,144) 35% (n=106J 
Table 2. Patients with erectile difficulties. Age and objective penile response (mm in= in circumference) following viSU:ll erotic stimulation (YES), 
YES eombined with vibrotacti!e stimulation (VIB), and following VES combined with intr.lc:lvemous injo:ction (ICI) with the vasoactive drug p~p~vmne. 
Values are mcuns±s.d. and medians 
VES VES+VIB VES+IC[ 
Age (yrs) n Mean±s.d. Median n Mean ± s.d. Median n Mean±s.d. Median 
::::40 86 1Z.a±1Z.1 9.5 31 15.5±14.0 12.0 , 24.1±11.9 31.0 
41-60 226 7.0±8.7 '.0 96 7.G±9.1 '.0 
" 
19.7±8.1 ZZ.O 
61 ::: 
" 
7.Z±9.Z 4.0 38 7.4±a.a 2.5 15 ZO.S±11.1 21.0 
ToW 389" a.4±9.9 '.0 16S 9.0±10.6 4.0 66 20.3±9.2 Z1.S 
• From 17 patients (4.06-389) thorough history taking rovealed adequate ponilo responsos, which mndo further psychophysiologicul 
investigation not nOC(lSSary. 
tions (median 2. range 0-60), spontaneous daytime 
erections (median o. range 0-60), sexual activity 
with a partner (median 2, range 0-28), masturbation 
(median 0, range 0-60) and erotic dreams (median o. 
range 0-8). 
Sexual difficulties can also be seen in Table 1. 
About half of the patients had severe problems with 
achieving an erection su££i.cient for intercourse. and 
almost 80% reported severe difficulties in maintain-
ing their erection. About one·third of all patients 
suffered (also) from 'premature ejaculation' (PE), 
and approximately 10% of patients reported severe 
difficulties or inability to ejaculate. It should be 
noted that many of the patients with ED also 
experience PE, not the classical form where they 
lack control. but they intentionally come relatively 
fast because otherwise they fear to loose their 
erection before orgasm/ejaculation. About half of 
the patients experienced fear of failure with sexual 
activity. 
Age 
Patients were grouped according to age into three 
categories: young (under 40y of age), middle 
(behveen 40 and 60), and older (61 and older) (see 
Table 2). The penile response data (mm increase in 
circumference) subjected to Kruskal-Wallis test 
revealed an overall significant difference between 
age groups for VES (p=0.001) and VES+VIB 
(P=0.026), but not for VES+ICI (P=0.56). Subse-
quent pairwise analyses with the Whitney test 
revealed that penile response data of the middle 
and older men never differed significantly, whereas 
the younger men differed from both other groups 
with VES (P < 0.01) and with VES + VIB (P < 0.025). 
VES combined with VIE or leI 
The mean penile response was highest with 
VES+ICI (20.3mm increase in circumference), 
followed by VES + VIE (9.0 mm) and VES alone 
(8.4mm). The 160 patients who were exposed both 
to VES and VES + VIB showed a Significantly greater 
penile response (Wilcoxon, P < 0.001) to VES + VIB 
(9.1mm±10.7s.d.) than to VES alone (5.5mm 
±7.6s.d.) and VES+ICI (20.6m.m±9.3s.d.; Wil· 
coxon P < 0.001). Of the 12 patients who were 
exposed to all three conditions it appeared that 
VES + ICI was most effective (21.8 rom ± 10.2 s.d.) in 
causing a penile response than VES (4.7mm 
±4.5s.d.) orVES+VIB (4.8mm±5.2s.d.). 
Subjective sexual responses 
Subjective sexual responses to VES, VES with VIB 
and VES with leI, are presented in Table 3. For 
sexual arousal it is obvious that the number of male 
patients that respond strongly increases from 46% 
with VES, to 61% with VES + VIB and 73% with 
VES+ICI. Similar results. somewhat more outspo· 
ken, were found for the strongest subjective penile 
response: 34% with VES. 52% with VES+VIB. and 
82% with VES +ICI. For both parameters a recipro· 
cal picture emerges for the percentages of patients 
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Table 3 Patients with eTectile difficulties (number and percenbges). 5=1 arousal, subjective penile response (1 nnd 2: no n:::;ponse; 5. 6, 7: partial_rull 
erection/cjne),:md patient's estimated degree of erettion (D-1OO"A.) following visual erotic stimulation (YES). VES combined with vibrobctilc stimulation 
(VIB), nn~ following VES combined with intmeavemous injection (IC!) with pnpaverine 
VES+ VIE VES+ICI 
l1em No Tesponsc Strong 
response 
Total No response Strong 
response 
Total No respon$o Strong Toiol 
response 
Soxunl arousal (1-7) 
Pcmilo responso {1-7} 
Penilo respoIlSu (0-100%) 
63 (17%) 168 (46%) 
128 (31%) 138 (34%) 
Mann: 30.7±Z8.6 
Medio.n: 24.0 
0",295 
(36l) 
(380] 
20 [13%) 96 (61%) 
30 (19%) 84 (52%) 
Moun: 41.9±30.9 
Median 35.0 
n=l44 
[156) 
[163) 
3 (5%) 45 (73%) (62) 
4 (7%] 54 (82%) (65) 
Moun: 67.2±26A 
Modian 68.0 
n=61 
Table 4 Nocturn:ll penile tumescence (NPT) dat:!. of patients who do no! report morning/night erections and patients 
who do experience morning/night erectionS. NPT -da.ta are means of 2 consecutive nighL~ (mm inerca~e in 
pcniscircumference) with yellow (250 gr expansion force). and 2 eonsecutive nights with green (450 gr expansion 
force) eTectiometer 
Morning/night erections 
" 
Yellow 
N,~ 78 13.3±10A 
Occnsionnlly/frCtqucnt 
(1 x por month or more) " 
17.8±8.7 
172 lS.0±10.1 
that do not respond (31%. 19% and 7% respec~ 
tively). The patients' estimated mean degrees of 
erection (o--100mm analog scale) were about 30% 
with VES, 42% with VES + VIB, and 67% with 
VES+lCI. 
When correlations were calculated between sub-
jective sexual arousal (semantic scale 1-7) and 
subjective penile response [semantic scale: 1 (no 
feelings), 6 (full erection), 7 (ejaculation/orgasm)] on 
the one hand and objective penile response (mm 
increase in circumference) on the other hand the 
following results were obtained. With VES. both 
sexual arousal and subjective penile response were 
correlated significantly with objective penile re-
sponse, that is mm increase in circumference 
(r5 =0.39, n=360. P<O.OOl and Is=0.62, n=378, 
P < 0.001 respectively). With VES + VIB similar 
results emerged: sexual arousal was correlated with 
objective penile response (rs=0.40. n=156, 
P < 0.001). With VES following lCI correlations were 
different between objective penile response and 
sexual arousal (ra=0.23. n=52, P<0.07), and 
subjective penile response (Xs=0.16, n=65, ns). 
Morning/night erections 
As can be seen from Table 4 many patients who did 
not report morning/night erections, did display 
these. however, when measured with erectiometers. 
With the yellow erectiometer 15 of 78 (19%) had a 
very low response (0-4mm), 20 (26%) scored 
between 5 and 10, whereas 43 (55%) had a good 
Medion G=" Median 
Mean±s.d. Mcan±s.d. 
10.5 10A±10.6 '.5 
1.8.5 15.0±9A 15.0 
15 13.0±lO.2 12.5 
score of 10mm or more. With the green erectiometer 
these figures were 39%,18% and 43% respectively. 
Furthennore, patients who reported morning/night 
erections responded significantly better than pa-
tients who 'never experienced morning/night erec-
tions (with yellow erectiometer 17.8 vs 13.3mm, 
P<O.OOl; with green erectiometef 15.0 vs 10.4mm 
P<O.OOl). 
Discussion 
In contrast to what has been suggested by Buvat and 
coworkersll it is clear from this present investigation 
that many older as well as younger men with ED 
showed a good penile response to VES. Men under 
40y of age responded significantly better than men 
over 40; between ages 40 and 80 y men did not differ 
in the penile response to VES. The addition of VIB 
to the VES significantly increased penile response in 
men of all ages. lCI combined with VES caused a 
very substantial increase in penile response in 
virtually all patients of all ages. In recent years, 
from 1994 onward, we combine ICI with VES + VIE 
which gives even better results. 
In somewhat more detail this means that YES 
caused no response in roughly one-third (31%) of 
the patients (n = 128) and a strong response (partial! 
full erection) also in one-third (34%). The combina-
tion of VES+ VIB administered to 163 patients, 
caused no response in 19% of the patients but a 
strong response in about half of them (52%). Finally, 
VES + ICI caused no response in only 7% of the 
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patients tested this way (n = 66) and a strong 
response in 82%. 
. From the present study it seems worthwhile to 
invite patients who do not experience morning! 
night erections to sleep with the erectiometers for 
four consecutive nights. More than 50% of such men 
appear to have good. rigid erections (it should be 
remembered that the erectiometers also indicate 
rigidity), This corroborates earlier results from our 
laboratory.l Although the RigiscanR undoubtedly 
provides more detailed information about nocturnal 
penile tumescence/a,lO the use of the RigiscanR 
could be restricted to 'difficult' cases when past 
history and erectiometers gave no or poor results.2() 
Although the use of both erectiometers has been 
suggested1 we no longer believe this to be useful. 
From the present study it appeared that there was a 
high positive correlation between measurements of 
the yellow and the green erectiometer (r= 0.75, 
P < 0.001). Therefore. we believe one could decide 
to use only the green erectiometer, which requires 
about 450 gr expansion force, for two consecutive 
nights. 
It is of interest to note that there were no 
significant correlations between NPT measurements 
and penile responses to VES, VES + VIE, or 
VES+ICI (all r between 0.09 and 0.30). This is in 
line with earlier assumptions that nocturnal penile 
erections might be different from daytime erections 
elicited by visual erotic stimuli.Zt-Zl 
A positive penile response to VES or to VES + VIB 
should be positively reinforced by the doctor to the 
patient: it shows that nothing serious is wrong. that 
the genital apparatus is basically capable of re-
sponding sexually. When no response occurs, one 
should be keen to reassure the patient and explain 
that such a response has no diagnostic signijicance. l 
Failure to respond may result from lack of interest, 
dislike of the film, anxiety, fear to lose control, 
etc.6.tl Although some urologists dislike the fact that 
a negative response has no diagnostic significance, 
we believe that the test nevertheless is very worth-
while because so many patients with ED show a 
positive response, which has diagnostic relevance. 
Recently. Bancroft and MaloneZ4 reported that 
'because of the high proportion of false negative 
results. ICI monitoring is of very limited diagnostic 
value' (p 123). We have earlier advocated6.z~ that ICI 
should be given in a sexually positive atmosphere, 
(that is a quiet private room, provided with sexually 
stimulating materials: video or magazines). to 
reduce the occurrence of faIse-negative results. 
Other investigators6 also reported that audiovisual 
sexual stimulation improved the response to ICI of 
pharmacologic agents. We suppose that the high 
proportion of false negative results in the Bancroft 
and Malone study24 could be the result of the 
presumably rather 'cold', asexual clinical setting in 
which the leIs were administered and the penile 
response was monitored. The results of the present 
study. 82% with a very strong penile response to 
ICI + VES, supports our supposition. Furthermore. 
in 1994, 70 men with ED received ICI plus 
VES + VIB and showed a mean increase in penile 
circumference of approximately 26 mm (at the tip of 
the penis, behind the phallus). and a mean sub-
jective penile erection of 82% (24% experienced an 
orgasm/ejaculation). 
When all results are taken into account, VES 
exposure and NPT information. we reach the 
following preliminary diagnoses: (primarily) psy-
chogenic 84% (n= 330). mixed organic and psycho-
genic 14% (n=54) and purely organic 2% (n=8). 
Although the number of patients with a psychogenic 
or primarily psychogenic diagnosis may appear to be 
high, this finding supports edJ.'lier reports from our 
outpatient clinic in which we found sexual potency 
in 71 % of men with ED.l There could be some bias 
in the patients who were referred to our psycho-
physiology laboratory: maybe some patients with 
very obvious organic problems were not always 
referred by the urologists. However. recent data of 
100 consecutive patients with ED of a urology 
outpatient clinic investigated with similar metho-
dology as in the present paper revealed a 50% 
purely psychogenic and 23% primarily psychogenic 
diagnosis.4 In the latter study 3% were pure organic. 
12% primarily organic. 7% mixed. and 5% of 
uncertain etiology. 
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Background We sought to establish relationships be-
tween current sexual functioning, the findings of 
initial psychophysiological screening (PPS) and the 
treatment undergone in patients with erectile dys-
function (ED). 
Methods A follow-up study (l-4 years later; mean time 
period 1.9) was carried out among 406 patients with 
ED, of which a representative sample of z. 37 respond-
ed. An extensive questionnaire was used including 
items dealing with the original medical examination, 
including PPS, treatment, subjective experience of the 
treatment and psychosexual functioning over the 
3 months prior to the questionnaire study. Question-
naire data. were linked with originally collec~ed PPS 
data, including the sexual-history data. 
Results Present sexu:il satisfaction was positively cor-
related with original numbers of spontaneous daytime 
and morning/night er:ections, but was not correlated 
with the degree of genital and sexual arousal elicited 
Introduction 
Psychophysiological screening (PPS) has been advocat-
ed as a useful adjunct in the procedures employed in the 
differential diagnosis of erectile dysfunction (ED). '-5 
PPS comprises the measurement of penile responses to 
explicit erotic stimuli, i.e. erotic videos with concomi-
tant vibrotactile penile stimulation and, in more recent 
years, combined with intracavernous injection (ICI) of 
vasoactive substances like papaverine, phentolamine or 
prostagl:mdine PGE\.6-S Through visual sexual stimu-
lation (VSS), attempts were made to produce a penile 
erection, proving that the neurovascular erection mech-
anisms are intact. It should be borne in mind that the 
absence of a partial or full erection during PPS has no 
conclusive diagnostic significance. }.9 
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by visual sexual stimulation (VSS). Treatment results 
were not satisfactory in 55% of patients. Autoinjec-
tion therapy (AIT) and psychotherapy yielded higher 
satisfaction scores than other treatments. In general 
men < 40 years appeared to be mOre sexually active 
and satisfied, and to experience fewer sexual problems 
than the older patients. 
Conclusions The occurrence of spontaneous daytime 
erections and morning/night erections, obtained by 
history taking, indicates a psychogenic cause of the 
ED, and has clear predictive significance for later 
sexual functioning. While a positive outcome of PPS 
suffices to make the diagnosis of non-organic ED, it 
does not, contrary to what we had expected, predict 
later sexual functioning. 
Keywords: erotic video, follow-up investigation, 
impotence, penile erection, psychophysiological 
screening. 
We have earlier suggested that a positive PPS response 
(the occurrence of an erection) could have a predictive 
value with respect to treatment outcome and could also 
have a therapeutic effect. '0 These suggestions could not 
be confirmed by V ruggink. " Both of these studies 
comprised relatively small groups of patients (43 and 37 
patients respectively) who were contacted by question-
naire or telephone interview, between ( and 4 years after 
the consultation for ED during which PPS was carried 
oue 
One rC:lson for carrying out the present follow-up 
study, in a much larger group of p:loents with ED, was to 
shed light on this apparent discrepancy in the possible 
predictive value of PPS. A second aim was to ascertain 
the current sexual functioning of these patients and to 
relate the follow-up d .. ta with those obtained during [he 
original medical exa.min:ltion for ED, between I :lnd 
4 years earlier. 
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Methods 
During the years 199I through to I993 a total of 45i 
patients with ED were referred to the psychophysiology 
laboratory, of which 406 (sec ref. 4) underwent complete 
PPS. One to 4 years later (end of 1994) 436 patients for 
whom the address was available were sent a question-
naire. Questionnaires were returned by 237 patients 
(54%),203 of whom had undergone complete PPS. 
There were 199 non-responders. 
Nearly all referred patients had undergone a phys-
ical examination by the urologist and a routine blood 
analysis. Complete PPS comprised an initial oral 
interview about personal, medical and sexual history, 
including sexual functioning and problems. Patients 
were also asked to fill out a number of fonn~ soliciting 
detailed information on current sexual functioning. I 
Subsequently, patients were exposed to :m erotic video 
(VSS) while changes in penile circumference and 
rigidity were measured with an erectiometer® (which 
requires approximately 250-g c.'Cpansion force'). Then 
V$S was repeated with another video, and with 
concomitant vibrotactile stimulation (VIB) to the 
underside of the tip of the penis (for details see 
ref. 9). If no response occurred, VSS with a third erotic 
video was combined with an intracavernous injection 
(ICI) of pap:!.Verine sulfate (other vasoactive subst.'l.nces 
were not used in those years). After each VSS 
subjective and genital arousal were filled oUt: on a 
questionnaire. It should be mentioned that we had not 
completely standardized our methodology in dut the 
sequence of the erotic stimuli varied from one patient 
to another. 
On the basis of the PPS findings the patient's sexual 
dysfunction was tenutively classified as (mainly) psy-
chological or (mainly) somatic. '-4 
In the present follow-up investigation an extensive 
questionnaire was used with items dealing with the 
original medical examination, including PPS and treat-
ment, the subjective experience of the treatment (if 
undergone), and the psychosexual (dys)functioning 
over the past three months. 
Non-parametric sutistics were applied: Kruskal-
Wallis test or Mann-Whitney V-test for comparisons 
between groups, and Wilcoxon's test for comparisons 
within groups. Correlation coefficients arc Spearman's 
(r.). P = 0.05 (two-tailed) was considered the limit of 
significance. 
This study was approved by the Medical Ethical 
Committee of Dijkzigt Academic HospiuVErasmus 
University, Rotterdam, The Netherlands. 
Results 
General data 
The age of the 237 responders varied from 21 to 82 years 
(me:m 52.5; median 54). The time between the original 
medical examination and the present follow-up in-
vestigation varied from x to 4 years (mean 1.9)· 
According to the recent, not always completed, ques-
tionnaire the patients reported that they originally 
suffered from erectile dysfunction alone en = 187; 
79%), or combined with premature ejaculation 
(n = 12; 5%), anorgasmia en = 6; 2.5%), low libido 
(n = 6; 2.5'%), anatomical defect en = 10",4%) painful 
erection (n = 6; 2-5%) and prostatism (n = ); 1%). 
Patients reported that they had originally undergone 
one or more of the following investigations: echocolorl 
dopplerofthepcnis(n = 49;2.1%), ICI (n = 149;63%), 
VSSNIB (n = 2.03; 86%), nocturnal penile tumescence 
(NPT) with erectiometers en = 115; 49%). 
Comparison of responders and non-rMponders 
The two groups were compared on the following 
relevant items: age, genital arousal during VSSIVIB 
(mm increase in penile circumference), NPT, frequency 
of morning/night erections, and frequency of sponta-
neous daytime erections_ None of these parameters 
differed significantly between the two groups 
(P ~ 0.23). We therefore conclude that the sample of 
responders adequately represents the whole patient 
population. 
Treatment u~der90ne 
Many patients declined to receive treatment after the 
initial screening. Some form of treatment was reported 
1:0 have been received by 54% (n = 128) of the patients. 
In many instances (n = 79) patients learned autoinjec-
tion therapy (Arr) with a vasoactive substance (papa-
verine or papaverine/phentolamine), or the use of a 
vacupurnp device (n = 30). Psychological treatment 
such as sex, relationship or psychotherapy was under-
gone by 19 patients, while 14 men received drug 
treatment (Yohimbine, Clomipramine or other). Sur-
gery was applied to five men with a prosthesis, and three 
men underwent vascular reconstruction. Comparisons 
of the efficacy of me various treatments will be discussed 
below. 
Only 35% (n = 45) reponed to be (reasonably) 
satisfied with the results of the treatment, 55% 
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(n = io) were (very) unsatisfied, 6% (n = S) were 
neutral, while 4% (n = 5) hiled to repon. In compar-
ison with 109 patients who had not undergone treatment 
the satisfaction with current se."(ual functioning did not 
differ significantly (P = 0.48). Within the group of 
patients that received treatment there was an overall 
difference in the degree of satisfaction varying with the 
nature of the treatment (P = 0.017), with highest 
satisfaction scores for leI (n = p; 3.4 ± LS SD) and 
psychotherapy(n = 12;3.2 ± 2.1 SD)andlowestscores 
for vacupump therapy (n = 12; 1.8 ± 1.1 SD). 
CUrrent treatment 
At the time of the present investigation 68 patients were 
still using some form of medical treatment: 37 ,men were 
using autoinjection therapy, six a vacupump device, four 
an clastic band, nine oral medication, and seven 'anoth-
er'. Again, the injection group had the highest satisfac-
tion scores. 
Comparison with original complaint 
More than half of the patients reported no change in 
their original complaint (n = 129: 54%), about one 
quarter of the patients (n = 57; 24%) reported an 
improvement, and 49 patients (21%) indicated a further 
deterioration of their scmal functioning. There ap-
peared to be an effect of age in a comparison between 
patients < 40, patients between 41 and 60, and patients 
> 60 years of age (P < O.OOI). The youngest group 
reported an improvement significantly more often than 
the twO older groups; the latter twO did not differ 
significantly. 
Comparisons with original PPS findings 
Correlations were assessed between present satisfaction 
scores and various items measured with the original 
psychophysiological screening. The genital arousal 
(millimetre increase in penile circumference) and se.'(ual 
arousal (seven-point subjective scale) in response to 
erotic video exposure (which correlated highly signifi-
cantly (7"~ = 0.67; P = O.OOI) with each other), were not 
significantly correlated with the present sexual satisfac-
tion score. Objective nocturnal penile tumescence 
(NPT) data as measured with the erectiometers, likewise 
failed to correlate with satisfaction scores. 
Significant correlations were obtained between pres-
ent sexual satisfaction scores and the origirL1.l occurrence 
of spontaneous daytime erections en = 191, 7". = 0.17; 
P = 0.0;:'), and the original frequency of morning/night 
erections en = 191, r~ = 0.;:.6; P = 0.001}. Morning/ 
night erections and present sexual satisfaction were 
significantly correlated for patients over 40 years 
en = 154,7", = 0.;:.6,P = 0.001), but not forrhe younger 
age group (n = 37)' 
Age and various current sexually relevant items 
In Table I various sociosexual parameters and sexual 
problems are enumerated for three different age groups. 
In general the youngest age group appeared to be more 
sexually active and satisfied, and to experience fewer 
sexual problcms than the oldest age group. On all 
parameters, with the exception of masrurbation fre-
quency, an overall comparison between the three age 
groups yielded highly significant differences. 
Discussion 
The prcsent study comprises a 54% sample of a 
population of +57 patientS with erectile dysfunction 
who had been referred to thc psychophysiology labo-
ratory over a 3-year period. The sample appeared to be 
representative of the total group by all relevant para-
meters. Many of the details obtained during the original 
medical eX3minarion, including psychophysiological 
screening (PPS), have been published before;"" In that 
publication we concluded that &4% of the cases were 
primarily of psychogenic origin, 2% were considered 
purely organic, while the remainder (14%) were of 
mixed organic and psychogenic origin. The percenuge 
of purdy organic cases is likely to be biased by the faCt 
th3t patients with very obvious organic causes wcre 
usually not referred to the psychophysiology laborato-
ry. In the prcsent paper we are concerncd with the 
results of a follow-up investigation through an extensive 
questionnaire I to 4 years after the original examination. 
Correlations were determined between present satis-
faction with sexu:d functioning and various d3u ob-
uined during the original psychophysiolOgical screen-
ing. Present sexual satisfaction was positively correlated 
with the original occurrence of sponuneous daytime 
erections, and with thc original frequency of morning! 
night erections. Present sexual ~tisfaction was not 
significantly correlated with the degree of geniul and 
sexual arousal during the original visual sexual stimula-
tion. Thus VSSNIB responses did not have a predictive 
value for later sexual functioning. This may be partially 
causcd by the variations, introduced during the original 
screening, in thc sequence in which thc stimuli were 
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Table: I Patients with erectile dysfunction: sociosexual par.tmeters and sexual problems observed over the bst.3 1l1onths prior to the 
recent questionnaire follow up. Note the importance of age for virtu<l.lIy all items presented. Values arc the means ± SEM 
Sociosexual paramctcrs Ag' Ag' Ag' Sralistics Total 
n $ 39 yr n = 40-00 yr n' 
" Y' 
(Kruskall-Wallis) n (all "g~s) 
RcLttionship duration (rr) 
" 
6.2:t r.o 
" 
20.-6 ± t.2 45 29.7 ± 2.2 P = 0.00! "7 20.4 ± J 
Relationship quality 3' 6.2 ± 0.1 102 5.2 ± 0.2 49 5.] ± 0.2 P == 0.008 ,S) 5-4 ± 0.1 
(! = vel)' unhappy; 7 =:: very happy) 
Coitus with orl;.lSm (freq.lmonth) 34 5.6 ± 0.8 '0' 4·} ± 0·5 J9 2.J ± 0·5 P = 0.004 176 4.1 ± 0·4 
Morning erections (freq.lmomh) B 11.4 ± 1.4 
" 
9.1 ± 1.0 43 6.1 ± 1.1 P = 0.007 "7 S.8 ± 0.7 
Masturbation (freqlmonth) 
" 
5.8 ± 0.8 
" 
4-7 ± 0.8 '7 }.2 ± 1.0 P = 0.00':: "9 4.6:t 0.) 
Quality of sex life 39 3.8 :t 0.':: ", 3.1 ± 0.1 '0 '::.9 :!: 0.2 p= 0.or7 .::.::8 3 . .:: :!: 0.1 
(J =: very bad; 7 "" excellem) 
Satisfaction with 5eXU:l,! functioning 4° +1 ±0.3 lP. 3.0 ± 0.':: 
" 
2.7 ± 0.':: P == 0.002 234 3.1 ± O.! 
(r = very low; 7 = very high) 
Sexual problems Ag' Ag' Ag' Statistics Total 
n $ 39 yr n = 40-60 yr n <!: 61 yr (KTuska/l-Wallis) n (all ages) 
No sexual desire 
" 
H ±0·3 ,,' 
SCXU:l,l problems with: 
getting an erection 
" 
5.0 ± 0·3 121 
sustaining an erection 
" 
4·5 ± 0·3 120 
Coitus impossible bec.1use of 
" 
5·0:t 0.3 "4 
insufficient erection 
Prem::tture ejaculation 
" 
4·4:!: 0·4 "4 
La.borious orgasm/ejaculation 
" 
5·9 :!: 0·3 
'" Fear of failure 
" 
5.2 ± 0·3 ,,' 
Partner nOt interested in sex 35 H ± 0·3 '07 
offered (VSS, VIB, VSS + VIB).A predictive value of the 
response during PPS may arise following the introduc-
tion of a complete standardized PPS methodology (sec 
below). 
About half of the patients (54%) h:J.d undergone some 
form of treatment; approximately one-third of these was 
satisfied with the results of the treatment, while 55% 
were dissatisfied. Autoinjection therapy (AIT; 79 pa-
tients), and psychotherapy (I9 patients) yielded higher 
satisfaction scores than other fonns of treatment. 
With regard to the original dysfunction, 24% of the 
patientS reported an improvement, 2I % a deterioration, 
while 54% experienced no change. 
These rather disappointing results (shared by other 
long-term follow-up studies. '2-'4) indic:l.te the need for 
a more appropriate therapeutic approach to patients 
with erectile difficulties. Ideally, the doctor should be 
able to choose from a broad spectrum of therapeutic 
possibilities relevant for the individual patient and his 
partner. Unfortunately, this was usually not possible for 
the patients reponed in this study. In recent years we 
have optimized our PPS methodology in the following 
manner. each patient first undergoes VSS, then 
VSS + VIB, and subsequently ICI if the penile response 
--- ... ~~~--- --~----
4.4 ± 0.2 
" 
4.4:!: 0.2 P == 0.02 .::n 4.6 :t 0.1 
3.5 :!: 0.2 
" 
'::.9 ± 0.':: P = 0.001 218 3.6 :!: o.! 
3.0 :!: 0.2 
" 
2.6 ± 0.2 P = 0.001 21 7 3 . .:: ± 0.1 
3.2 ± 0.2 
" 
2.6 ± 0.2 P = o.oo! 20~ 3.4 ± 0.2 
4.r :t 0.2 53 ,.2 :!: 0.3 P = o.o! '0, 4.4 ± 0.2 
4.S ± 0.2 54 4·4 ± 0·3 P = 0.001 ,::oJ 4.9 ± 0.1 
3.9 ± 0.2 P 3.8 ± 0·3 P = 0.007 203 4.1 :!: 0.2 
5.':: ± 0.2 49 4·4 ± 0·3 P =:= 0.0':: ", 5.0 :!: 0.1 
is unsatisfactory.J·9 Data obtained so far with this new 
procedure applied to our 1994h995 patients (n = 384) 
showed that an ICI of a small dose of prostagbndine (5-
IO).l.g) or papaverine/phentolamine (0_5-I ml) resulted 
in a full erection in nearly all patients who had not 
achieved one with VSS and VSS + VIB.'5 Prolonged 
erection (lasting 4- 6 h) occurred in 6% of cases. These 
latter data. confirm our earlier suggestion. in which we 
advocated the combined use of an erotic positive 
;:ltmosphere with ICI.'(i In addition to the improvement 
of our PPS methodology, we have added the availability 
of psychosexual counselling in combination with so-
matic treatments such as AIT, vacupump and drug 
medication. Continued evaluation, short term as well as 
long term, of these procedures remains obligatory to 
ensure optimal diagnosis and treatment of men with 
erectile dysfunction. 
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Objectives To evaluate retrospectively the body image 
and sexual functioning in patients who have a tcsticu.~ 
lar prosthesis (TP). 
Patients and methods The medical charts were evaluated 
for 30 adult patients who received 32 TPs between 
1985 and 1997. A questionnaire was mailed to each 
patient. asking about body image. satisraction with 
the implant and with sexual functioning. 
Results Of the 30 patients, 22 (73%) replied: their mean 
(range) age was 30 (18-47) years. Most ofthc'patients 
had a silicone gel-filled TP. No complications wcrc 
reported in 25 (83%) patients and 80% reported no 
sexual problems: 20% felt uncomfortable in intimate 
contacts. 68% found their body image improved after 
Introduction 
'To have balls' is a popular expression in Southern 
European countries (and elsewhere). indicating that a 
man is courageous and strong [IJ. Surgical castration. 
trauma or agenesis of a testicle may produce psycho~ 
se..,.-ual dysfunction. espeeiaUy in young men. Testicular 
prostheses (TPs) have been used since 1941: the first 
(made of vltallium) was implanted in a 27~ycar-old 
patient who lost a testicle after trauma and subsequently 
became depressed [2J: the depression resolved after the 
implantation. There arc relatively few studies reporting 
on the outcome of implanting a TP and in only two 
papers were the patients' perceptions assessed [3.4]. In 
no reports have the se),:ual aspects of having an implant 
been evaluated. Thus the present study was conducted 
to evaluate retrospectively the body image and se:\"UaJ 
functioning in patients with a TP. 
Patients and methods 
The medical charts were evaluated for 30 men who had 
had a TP implanted at our hospital during 1985-97~ 
the reasons for insertion. the side and size of the implants 
and possible complications were retrieved from these 
Accepted [or pubUcntlon 21 July 1999 
having a TP. 58% were satisfied with their current 
sexual life. 90% had no erectile dysfunction and 45% 
reported premature ejaculation. 
Conclusions Patients who have lost a testis for any 
reason should be informed about the availability of a 
TP. Prostheses were well accepted and no systemic 
disease was reportl!d. Almost all patil!nts reported an 
improvement in their body image. Sexual life and 
performance were apparently not compromised by 
having a TP. New surgical procedures are rec~ 
ommended to improve the cosmetic appearance of a 
TP in the scrotum. 
Keywords Testicular prosthesis. body image. sexual 
function 
charts. A questionnaire was mailed to each patient, and 
they were invited to visit the outpatient cHnie for an 
interview and a cosmetic evaluation. The questionnaire 
consisted of two parts: the first nine questions dealt with 
body image and satisfaction after insertion. and the 
second part consisted of 24 questions concerned with 
sexual functioning (possible problems with erections. 
premature ejaculation. frequency of sexual activity) and 
satisfaction about sexual life. Some patients did not 
answer all the questions. 
Results 
The questionnaire was returned by 22 patients (73%): 
]:::; patients (60%) attended the hospital for an interview 
and a cosmetic evaluation of the implant. The mean 
(range) age of these patients wa:;; 30 (l8-47) years. Of 
the eight patients who did not reply. four were lost to 
fo!!ow~up and four refused to participate in the evalu~ 
ation. The reasons for and the side of insertion arc 
shown in Table·l. fn three patients the TP had been 
re-implanted. in one because the TP inserted In another 
hospital had ruptured. and in two because they needed 
a larger TP. One patient had undergone a vasectomy 
and 11 patients had undergone previous inguinal sur~ 
gery because of orchidopexy or inguinal hernia. In the 
26 men who had undergone orchidectomy. the mean 
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Table 1 Reasons for. side of insertion. type unci size of the: lcsticulur 
imphmlln 30 patients. :lnd In parentheses for the 22 who rdurned 
the (jllcstlonnalrc 
Variable Number 
Rrasolls 
Undescended 11 j1\) 
Cancer 7 IS) 
Agenesis 5(3} 
Torsion (, (5) 
Puln 1 (l) 
Side 
Right 12 (7) 
Ldt 16{l3) 
Both 2 (2) 
T!JPc 
Gel-filled 22 (15) 
Unknown gcl-fliled or solId 10 (9) 
SI:..-
Medium 6 (5) 
""g' 21 (lS) 
Unknown 5 (4) 
(median. range) interval between orchidectomy and 
insertion of a TP was 51 (20. 0-228) months. The type 
and size of TP is shown in Table l. 
At our hospital. the TP is inserted via an inguinal 
incision: a scrotal pouch is created bluntly and the TP 
is subsequently fixed with one suture to the lowest point 
in the hemiscrotum. Patients received prophylactic anti-
biotics on the day of surgery. In 25 patients (83",\,) no 
complications were reported. One patient (3%) com-
plained of postoperative pain and two (7%) had a scrotal 
haematoma which needed no treatment. Three paticnts. 
among whom was the one who had a haematoma. 
reported a cranial migration of the implant. Two of these 
patients were re-operated to reposition the TP. There 
were no infections. 
Three of 21 patients (14%) reported that the implant 
had the same appearance and consistency as the remain-
ing testis; 12 (57%) considered it slightly different and 
six (29%) judged it completely diITerent. Sixteen of 20 
men reported no sexual problems and four felt 
uncomfortable in intimate contacts with their pi.lrtner. 
Eleven of 21 patients (52%) reported no problems in 
being naked with other men. while eight (38'Y.,) did not 
undress in the presence of other people because they 
were embarrassed. There were no significant correlations 
between the appearance of the TP and the occurrence 
of problems in intimate contacts with their partner. 
being naked with other men or undressing in the 
prescnce of others. 
Nine of 22 men (41%) considered thcir body appcar-
ance greatly improved after rcceiving a TP: six (27%) 
reported a slight improvement. in six (27%) there was 
no change and one (5<'>/<.» reported it to be worse. There 
were no systematic differences between patients with or 
without cancer (as a cause of testicular loss) in any of 
the variables assessed. Twenty-one of the 22 (95%) men 
would undergo surgery again if necessary. 
Eleven of 19 men were satisfied with their sexual life: 
16 reported spontaneous erections at night or during 
the day (mean frequency 12/month. range 0-28). The 
mean (range) masturbation frequency was 6 (0-28)/ 
month and se::-.."ual activity with partner 9 (O-12l/month. 
Seventeen of the 19 patients reported being always able 
to obtain or maintain an erection sufficient for sexual 
intercourse. while two had problems. Eight of 18 men 
reported premature ejaculation and one of 15 indicated 
fear of failure in sexual matters. 
The cosmetic evaluation showed a tight implant in all 
patients. which caused an asymmetric scrotal appear-
ance. also described by each man as 'different" from the 
normal anatomy. No systemic disease was reported in 
any of the patients. 
Discussion 
There arc only two studies reporting on patients· percep-
tions of a TP [3.4] but assessments of the sexu<.!l aspects 
of h<lving a TP are lacking: the present questionnaire 
study tried to address this issue. Of the present patients. 
68% reported an improvement in their body appearance 
after insertion of a TP. These results corroborate with 
the findings of Lynch and Pryor [4] and Gritz ct al. [5]. 
It is possible thallosing a tt.."Sticie through hcmicastration 
causes more concern about masculinity and body image 
than growing up with one testis because of maldescent 
of the second. In the present 30 patients. 14 had 
undergone (hemilcastraUon and 11 had one undes-
cended testis. There were no differences in the improve-
ment in body image after having a TP between patients 
with an und<.."Scended testis and patients who were 
(hemi)castruted. 
Sexual dysfunction has been reported in patients cas-
trated because of testicular cancer [5.6J. but not ufter 
receiving a TP. Of the prescnt patients. 11 % reported 
having problems with erections and 45% complained of 
premature ejaculation; 58% were satisfied with their 
sexual life. These data are similar to those reported for 
a group of young men treated for testicular cancer 
(orchidectomy with or without a subsequent TP) [3]. 
Although not specifically assessed in the present study. 
the low frequency of sexual problems could be rdated to 
the positive body image and the high satisfaction rate of 
these patients after in:;crtion of a TP. 
:-.Jo complicutlons were reported in 83% of the patients. 
a rcsul! in accordance with other reports l7i. None of 
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the present patients had a ruptured TP; although such 
rupture has been reported, it seems to have no medical 
consequences [8J. Patients who have undergone previous 
scrotal surgery have a greater complication rate than 
men undergoing insertion at the time of orchidectomy 
[9]. In the prescnt study, there was only one patient 
with previous scrotal surgery (a vasectomy) and this 
was also the only patient reporting pain after insertion 
of a TP. 
There was no systemic disease in these patients poss-
ibly related to a silicone TP. Particle shedding and 
migration from silicone genitourinary prosthetic devices 
has been reported. but with no clinical implications 
[10,I1J. Cosmetically. the currently used implants are 
far from ideal. The TP in aU the present patients was 
judged to be too high and too tight in the scrotum. New 
surgical procedures are required to improve U1e cosmetic 
appearance. e.g. not suturing the IT to the scrotum. 
Patients with sutured TPs should be tought to m'assagc 
the implant to avoid capsular tissue. which makes the 
implant too firm: this could also help to give a more 
natural feeling. 
In conclusion, the implantation of a TP is simple. has 
a very low complication rate and a high satisfaction rate 
in patients. The body image is greatly improved afLer-
receiving a TP and sexual dysfunction is minimized. No 
systemic disease related to the silicone TP was reported. 
Men of any age (and their partners) benefit from the 
restoration of normal social and sexual functioning. 
Suturing the TP to the scrotum is not recommended. as 
it CCllISCS an unnatural appearance. 
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LOW-DOSE RADIOTHERAPY IN 179 PATIENTS WITH PEYRONIE'S 
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Purpose: To analyse retrospectively treatment outcome in patients irradiated for pcyronic's disease. 
l\1ethOds and Materials: The records of 179 patients., median age 52 years, that rcccivl.'d radiotherapy (RT) 
between 1982 alld 199'rwcl;1! reviewed. 78% presented with painful erections and 89% with penile deformity. The 
symptoms were present for a median duration 0(6 months (range, 1-72 months). TIle RT sehedu!e consisted of 
13.5 Gy (9 x 1.5 Gy,3 fr:lctions per week) using: ortbovoltage X-r:lys in 123 patients or 12 Gy (6 x 2 Gy, daily 
fractions) using cieetrons in 56 patient~. A questionnaire regarding eurrent sexual functioning was mailed to 130 
patients whose addresses could be tr:leed; 106 (82%) responded. 
Results: At mean (ollow-up period 0£3 months, 83% reported that pain was diminished or had disappeared after 
RT. I wenty-three percent of patients reported a decrease in penile deformity. Following RT, surgical eorrection 
of penile eurvature was performed in 29% of patients. No RT-related complicatiOnS oecurred except transient 
dysuria in 1 patient. Questionnaire data: 72% of patients were currently sexually active, 48% had erectile 
dysfunction. and 49''10 expressed dissatisfaction with their current sexual functioning. 
Conclusion: Low-dose extemal RT (12-13.5 Gy) results in rdief of pain in the majority of patients with 
pcyrome's disease. Improvement in penile deformity was observed, avoiding surgery in a number of patients, No 
significant RT_associatcd morbidity was encountered. It is disappointing that almost 50% of patients complain 
of sexual functioning, but this is presumably not rel:ited to radiotherapy. to 2000 Elsevier Science Inc. 
Peyronie's disease. Radiotherapy, Fibrosis, Sexual functioning. 
INTRODUCTION 
Peyronie's disease was named for Francois Gigot de la 
Peyronie, a French surgeon who in 1743 described a fibrous 
cavemositis due to nodes in the corpora cavemosa, accom-
panied by penile curvature and discomfort with erection (1). 
The curvature is the result of a plaque of scar tissue in the 
tunica albuginea of the penis, limiting expansion during 
tumescence. The etiology and pathogenesis of Peyronie's 
disease is not yet completely understood. A proposed model 
is that Peyronie's disease is initiated by a trauma, i.e., 
mechanical stress during sexual intercourse (2). This leads 
to rupture of microvasculature in subjects with genetic 
predisposition for fibrosis, together with loss of tissue elas-
ticity as a normal aging process. Vessel damage causes 
deposition of fibrin in tissue space consequently promoting 
ingrowth of inflammatory cells. maerophages, and fibro-
blasts resulting in pathological penile fibrosis with plaque 
formation and even ossification in advanced disease (2). 
Unsatisfactory medical treatmcnt options for Pcyronie's 
disease include oral Vitamin E. potassium amino-benzoate 
Reprint requests to; Dr. Luca Incroeei. Department of Radi· 
ation Oncology, Daniel dcn Hoed Cancer Centre, Groene 
Hilledijk 301, 3075 EA Rotterdam, The Netherlands. E-mail: 
lncrocci@rtdh.azr.nl 
(potaba), colchicine, tamoxifen, or intralesional injections 
with verapamil, corticosteroids, or collagenase. Surgery re-
mains an option for nonresponders and in case of severe 
penile deformity. Radiotherapy has been previously re-
ported as a successful treatment modality. Treatment out-
come (n = 139) and current sexual functioning (n = 106) of 
a total of 179 patients irradiated for Peyronie's disease at 
our clinic arc the subject of this paper. 
METHODS AND MATERIALS 
The radiotherapy records of 179 patients treated for Pey-
rome's disease in the period, 1982-1997, were reviewed. 
Median age at treatment was 52 years (range, 25-76 years). 
One-hundrcd-thirty-nine patients (78%) presented with 
painful erections and 159 patients (89%) with penile curva-
ture; 34 patients (19%) reported erectile dysfunction. Symp-
toms were present for a median duration of 6 months (range, 
1-72 months); 30 men (17%) had received prior oral ther-
apy (Vitamin E, corticosteroids), surgery, or other treat-
Presented at the 41st Annual Scientific Meeting of the Amerie::m 
Society for Therapeutic Radiology and Oncology: San Antonio. 
TX; October 31-November 4, 1999. 
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Table 1. Patient demogrophics (n = 179) 
Median (mnge) age (years) 
Median duration (mnge) of symptoms (months) 
Dupuytren's contmcturcs 
Diabetes mellitus 
Hypertension 
Penile trauma 
Plaque location 
Dorsal 
Ventral 
So" 
Unknown 
Number of plaques 
0" 
Two 
Unknown 
Median plaque surface (range) (cm 2) 
52 (2$-76) 
6 (1-72) 
n(%) 
30 (17) 
12 (7) 
4 (2) 
20 (II) 
169 (94) 
6 (3) 
I (l) 
3 (2) 
158 (88) 
J 1 (6) 
10 (6) 
3.3 (0.5-18) 
mcnts unsuccessfully. Thirty patients (17%) reported Du~ 
puytrcn's contractures, 10 patients (5.5%) reported a penile 
trauma during sexual activity, and 10 more patients a penile 
trauma without erection. Patients' demographics arc sum-
marized in Table 1. 
At the time of this retrospective analysis (July 1998) a 
IS-item questionnaire regarding sexual desire, sexual activ-
ity. quality of erections, and satisfaction with sexual life was 
mailed to the 130 patients who could be contacted by phone 
or by mail (14 patients had died. 35 were not traceable). 
One-hundred-six men (82%) responded; 12 men did not 
want to answer the questions. 12 more men did not return 
the questionnaire. even after a second mailing. 
Radiotherapy 
Two treatment regimens have been used following the 
years. Orthovoltage radiotherapy with a median of250 kV 
photons (range, 120-250 kV) was used in 123 patients 
(69%); they received a total dose of 13.5 Gy, in 3 fractions 
of 1.5 Gy per week, followed by a second and third course 
after 3-4 weeks interval. Fifty-six patients (31%) received 
a total dose of 12 Gy in 6 fractions of 2 Gy daily, using 
clectron beams, median 10 MeV (range. 4-14 MeV) and 
bolus material. Target volume was the plaque area with 
generous margins, mostly the entire length of the penis. 
excluding the glans (median surface 48 cm2, range, 12-120 
cm:). A single portal was used; a 5-mm lead shield was 
always used to protect testicles, scrotum, and suprapubic 
region. 
Statistical methods 
Percentages were compared using the i or the Fisher 
exact test. The Mann-Whitney test was used to compare: 
graded outcomes and continuous data betWeen graups. p "" 
0.05 (two-sided) was considered the limit af significance. 
RESULTS 
One-hundred-thirty-nine patients (78%) attended fal-
low-up after a mean period of 3 months (range. 0-13 
months). Eighty-three percent of patients reported that pain 
with erect penis was diminished or had disappeared com-
pletely after radiotherapy; penile curvature was diminished 
or had disappeared in 29 patients (23%), and erectile func-
tion was improved in only 3 men (8%) after radiation. At 
physical examination, fibrotic plaques were smaller in 44 
patients (32%) and had disappeared in 10 patients (7%). 
Symptoms prior to radiotherapy and treatment outcome of 
the 139 patients wha attended follow-up is summarized in 
Table 2. Response to radiotherapy treatment was mostly 
achieved within 3 months (72% of men). A single patient 
(0.6%) reported transient dysuria during radiation. At fal-
low-up, 33% of patients had further been treated with sur-
gery (41 men), Vitamin E (I man), oral corticosteroids (3 
men), and ultrasound (I man). Patients who had been op-
erated had all penile curvature. There was no association 
between pain and penile curvature and plaque surface at 
presentation. Smaller plaques and longer follow-up seemed 
to correlate with better treatment results, althaugh this was 
not statistically significant. Younger age at treatment was 
correlated with better pain decrease (p "" 0.05), but not 
with improved decrease in penile curvature (p "" 0.63). 
Regarding decrease in penile curvature there was a trend 
that orthavoltage gave better results than electron beams 
(respectively 28% and 11%, p "" 0.06); in patients treated 
with electron beams the best results were obtained with 
bolus material, 18% vs. 8% without (p = 0.57). 
Sexual functioning questionnaire 
The median age of patients who responded to the ques-
tiannaire was 59 years (range, 35-84 years). Not all patients 
answered all the questions. Sixty-eight patients (72%) were 
Table 2. Symptoms priar to radiotherapy and treatment outcome of 139 patienL<: at follow-up 
Response 
Incidence Na change Diminished Disappeared Worsened Unknawn 
Symptoms n (%) n (%) n (%) n (%) n (%) n(%) 
Penile pain 119 (86) 17 (14) 45 (38) 53 (45) 4 (3) 0(0) 
Penile curvature 130 (94) 85 (65) 24 (19) 5 (4) 11(8) 5 (4) 
Erectile dysfunction 36 (26) 19 (53) 3 (8) 0(0) 1 (3) 13 (36) 
Fibrous plaque(s) 139 (100) 72 (52) 44(32) 10 (7) 6 (4) 7 (5) 
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scxualfy active; ofthcse. 34 (51%) and 41 (61%) of 67 had 
problems sometimes or always in, respectively. getting or 
maintaining an erection sufficient for sexual activity. Only 
one·third of the patients sought therapy for their erectile 
dysfunction. Overall 49% of patients (45/92) expressed 
dissatisfaction with their current sexual life. 
DISCUSSION 
The origin ofPcyronic's disease or induratio penis pbs-
tica. typically occurring in middle-aged men, is not yet 
completely understood. Trnuma of the penis with subse-
quently deposition of fibrin and fannatien of a fibrotic 
plaque is the most likely pathophysiologic mechanism (2-
4). Epidemiologic studies have shown a threefold increase 
of Pcyronic's disease among patients with previous genital 
or perineal traumatisms (5). The relationship betwecn Pey-
ronic's and Dupuytren's disease, a progressive contracture 
of fingers leading to distorted hand functioning. has been 
prcviously reported (2, 6, 7), in a percentage similar to our 
group of patients (17%). In Dupuytren's contractures, the 
presence of fibrin in the hand nodules has been confirmed 
(8). Because of the hypothesis of an inflammatory etiology, 
cmpirical treatments have been tried with unsatisfactory 
results. Vitamin E, bccause of its antioxidant effect prevent~ 
ing fibrosis, was already uscd in 1948 by Scott and Scardino 
(9). They reported a 91% dccrease of the plaque size and 
78% of penile curvature (9). Wagenknecht summarized data 
from 2752 patients treated with Potaba reporting a subjec. 
tive improvement in 60% of patients (range, 10-82%) (10). 
Akkus et al., in 1994, reported on 24 patients treated with 
oral colchicine: II % noted a slight decrease and 26% a 
marked decrease of curvation, 78% had rcduction of pain 
(11). Intralcsional therapy with co!iagenasc has bcen used 
by GcIbardet al. with curvature dccrease in 65% of patients; 
only mcn with less than 30° curvature and less of 2·em 
plaque size notcd actually substantial improvement (12, 13). 
Intralcsional verapamil, a cakium..channcl blocker, modi-
fies fibroblast phenotype reducing synthesis and secretion of 
coHagen and increasing collagenase activity (14). Levinc 
treatcd 38 patients with intralesional vcrapamil and noted a 
rapid reduction of pain in 97% and of curvature in 76%, 
after a follow-up of 24 months (15). Several surgical ap-
proaches have been used, from plaque excision with dermal 
grafting to correction of penile dcformity without tissue 
excision (16). Surgery may result in penile shortcning or 
diminished penile sensitivity, which is unpleasant for the 
patient; and results are not more successful than noninva~ 
sivc approaches (17). Only severe angulations making in· 
tercourse impossible should undergo surgery; in most pa-
tients with Peyronie's disease pain is the only symptom they 
seek thcrapy for. Radiotherapy for Peyronie's disease has 
been used since 1939 (6, 7, 18-29). Carson et al. reported 
on 40 patients treated with ortbovoltage radiotherapy in 
doses between 6 and 16 Gy (average, 9 Gy); 78% had a 
decrease of pain and 6% of curvature; no improvement of 
erectile function was noted (IS). Viljoen et al. treated 42 
patients with an average total dose of23 Gy and 47 paticnts 
with 25 Gy, with 250 kV orthovoltage radiotherapy (7). A 
questionnaire to assess long~term results at 33 months av· 
erage was mailed to all patients, 47 were returned and 
adequately completed. Pain was reduced in 84%, angulation 
in 38%, and 7% had an improvement of erectile function 
(7). Rodrigues et a1. treated 3S patients with 200-250 kV 
orthovoltage radiotherapy to a total dose of9 Gy (3 x 3 Gy, 
5 alternating days); 16 patients had still complaints after this 
schedule and were irradiated again with the same tcchnique 
up to a total dose of 18 Gy (6). The overall results were a 
decrease of penile pain in 76% and of curvature in 48%, 
60% had improvement of sexual life. No complications of 
radiation were reported (6). In our group of patients, pain 
was decreased or had disappeared in 83% and curvature, in 
23%. These results are similar to figures reported in the 
literature (6, 7, IS). There are reports stating that Peyronie's 
disease is self-limiting in 50% of untreated patients and 
improves spontaneously within 12-18 months (30, 31). 
However, 72% of our paticnts experienced pain relief within 
3 months, following radiotherapy which is considerably 
shorter than the possible normal evolution of the disease 
(30,31). It is understandable that men who desire sexual 
activity and experience erectile discomfort do not want to 
wait too long to find a solution for their problem. Patients 
wcre rcferred to us by the urologist, to be treated immedi· 
ately, when no spontaneOUS improvements occurred after a 
6·month (median) observation period. Erectile function im· 
proved in a low percentage of patients after radiotherapy 
treatment (S% in our group), demonstrating that the etiology 
of this dysfunction is much more complex than only a 
plaquc. Seventy·two percent of patients who responded to 
our questionnaire were sexually active, but also expericnced 
problems getting (51%) or maintaining (61%) an erection. 
This could be explained as due to the aging process; patients 
did not consider their erectile or sexual dysfunction as a 
consequence of their radiation treatment. No radiation·in· 
duced malignancy has been reported in our patients or in the 
literature with such doses. We currently use a daily frac~ 
tionation dose of 2 Gy to a 12 Gy total dose. with electron 
beams, ·S-10 MeV. and bolus material, confined to the 
plaque plus generous margins, with shielding of scrotum 
and suprapubic region. With this modality, no complica-
tions have been reported. We understand that a group of 
control patients would have been ideal for a thorough com· 
parison with our radiation treatment results. Unfortunately, 
this was not possible, because patients with Peyronic's 
disease, after a short period of observation, were referred to 
our hospital for radiation therapy, because of persisting 
pain. In our opinion, it would be difficult to initiate a 
randomized, prospcctive study comparing radiation and no 
treatment, because of the small number of patients referred 
for radiotherapy (5 patients per year in our center and 40 in 
the whole (If The Netherlands in 1997). We are aware of the 
limitations of a retrospective analysis. However, an on· 
going prospective study at our hospital with evaluation of 
complaints prior to radiation treatment and of outcome 3 
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and 6months after radiotherapy, using questionnaires, show 
similar results. In both studlcs most of the patients are 
satisfied with the results of radiotherapy and do not need 
surgery afterwards. The small percentage of patients in the 
retrospective analysis who had surgery following radiation 
all had severe penile curvature with no possibility of sexual 
intercourse. It is disappointing that almost 50% of our 
patients express dissatisfaction with their current sexual life, 
and 51% has difficulty getting an erection. Although a 
control group for comparison is lacking, we have no rcason 
to believe that sexual complaints are related to rndiation. 
Nevertheless. these data indicate that sexual counseling in 
patients witb Peyronic's disease before and aftcr radiother~ 
apy is highly recommended. 
CONCLUSION 
Low~dosc (12-13.5 Gy) external radiotherapy seems to 
be effective in patients with Peyronie's disease who 
complain of painful crections that do not disappear after 
a wait-and-see period. Improvement in penile deformity 
is also observed, reducing the need ofsurgicai correction. 
Surgery remains a good option in cases with severe 
curvature when sexual activity is impaired and when pain 
has not disappeared spontaneously or after radiation 
treatment. Radiotherapy is a noninvasive, not expensive, 
outpatient procedure with a high satisfaction rate and 
with no morbidity at such doses. Randomized, controlled 
studies are lacking. 
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CURRENT SEXUAL FUNCTIONING IN 106 PATIENTS WITH 
PEYRONIE'S DISEASE TREATED WITH RADIOTHERAPY 9 
YEARS EARLIER 
LUCA INCROCCI, WIM C. j. HOP, AND A. KOOS SLOB 
ABSTRACT 
Objectives. To analyze retrospectively the sexual functioning and treatment outcome in patients after 
radiotherapy (Rn for Peyronie's disease. 
Methods. During 1982 to 1997, 179 patients with Peyronie's disease were treated at our radiation 
oncology department. One hundred thirty patients whose address could be traced were sent a questionnaire 
about their symptoms before RT. treatment outcome. and current sexual functioning (the past 4 weeks). One 
hundred six patients. mean age 59 years, responded. 
Results. Before RT, 44% reported painful erections, 97% penile curvature, and 18% erectile dysfunction. 
Sixty-nine percent reported that after RT, penile pain was diminished and 29% that penile curvature was 
decreased; 13% reported improved erections. With respect to their current sex life, 51 % reported some-
times or always having problems getting an erection and 61 % in maintaining an erection; 36% never 
experienced spontaneous erections. Fifty-four percent reported not having erections rigid enough for sexual 
activity. Since RT (mean 9 years), there had been a moderate or severe decrease in sexual interest (l7%), 
sexual activity (41%), and sexual pleasure (32%). Overall. 49% of patients were dissatisfied with their 
current sexual functioning. 
Conclusions. Low-dose external RT resulted in relief of pain in two thirds of patients with Peyronie's disease. 
An improvement in penile curvature was reported in one third of patients. One half of men reported 
problems in getting an erection. The rigidity of erections was satisfactory in only 54%. There was a moderate 
to severe decrease in sexual interest, activity, and pleasure after RT: however. this was associated with age, 
although comorbidity or medications cannot be excluded. UROLOGY 56: 1030-1034,2000. ID 2000, 
Elsevier Science Inc. 
Peyronie's disease (PD) is a benign condition in which a plaque of scar tissue in the tunica al-
bUginea of the penis produces penile curvature and 
possibly discomfort with erections. The etiology 
and pathogenesis are not completely understood. 
A prevalent hypothesis is that trauma to the penis 
during sexual activity leads to rupture of vessels, 
with subsequent deposition of fibrin, resulting in 
pathologiC penile fibrosis and plaque formation. 1 
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Many treatment options (eg, vitamin E, corticoste-
roids, intralesional verapamil, and collagenase) 
have been used, with varying satisfactory out-
comes. ~ It is also possible to refrain from treat-
mem, since PD can be self-limiting in many pa-
tienrs. However, if penile discomfort is severe, 
therapy is necessary. In the latter case, radiother-
apy (RT) can be an effective treatment modality. 
Obviously, in cases of severe penile curvature, sur-
gery remains the therapy of first choice. The sexual 
function in patienrs with PD after RT is a much 
neglected area; it has not been studied in any de-
tailed manner. Therefore, the present study was 
undertaken to determine the current sexual func-
tioning of patients and treatment outcome in retH 
rospect. The study population consisted of 106 pa-
tients with PD treated with RT in our radiation 
oncology department. 
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TABLE!. Sexual desire in the past 4 weeks and significance of sex 
Did you have sexual desire? (n "" 92) 
How significant is sex for you? (n = 91) 
Not at All 
9 (10) 
5 (5) 
A Little 
20 (22) 
30 (33) 
Some 
45 (49) 
0(0) 
Much 
14 (15) 
48 (53) 
Very Much 
4 (4) 
8 (9) 
TABLE II. Frequency of spontaneous erections in the past 4 weeks 
Never 1/wk 2-6!wk l/day ~2Jday 
Did you have a spontaneous erection? (n "" 91) 33 (36) 25 (27) 19 (21) 10 (11) 4 (5) 
MATERIAL AND METHODS 
During 1982 to 1997, 179 p:ltients with PI) were trc:lted 
with RT. The tre3tment mochlity was t:lken from the medical 
charts. We could tmce 130 p:lticnts. They WCfe sent a ques-
tionnaire on treatment outcome and current (ie, the P:lSt 4 
weeks) sc,"(ual [unction. Questions regarded the presence of 
penile pain and curvature before RT, the dUr:1tion of symp-
toms, the response to treatment, and possible side effects. The 
sexual function questions concerned sexual desire, signifi-
cance of sex, frequency and rigidity of spontaneous erections, 
difficulty in gening or maintaining an erection, rigidity of 
erections duringse."(ual activity, and overall satisfaction with 
current sexual life. Patients were also asked whether a de-
crease of sexual intcrest, activity, and pleasure had occurred 
since RT. The sexual questionnaire was adapted from a stan-
dard questionnaire used during the past 10 years in screening 
men v.'ith erectile dysfunction {ED).3·4 
RADIOTHERAPY 
Sixty-four patients (60%) were treated using orthovoltage 
x-rays (9 X 1.5 Gy, three fractions weekly, median energy 250 
kV, range 120 to 250) and 42 patients (40%) with electrons 
(6 x 2 Gy, daily fractions, median energy 10 MeV, range 4 to 
14). The penile plaque plus the margins was the target volume 
(median surface 48 em2, range 12 to 120). The suprapubic 
region, scrotum, and testes were al~ys shicJded with 5-mm 
lead sheets. 
STATISTICAL ANALYSrS 
Percentages were compared between groups using the chi-
square or the Fisher exact test; within-group comparisons 
were made using McNemar's tcst. The Mann_Whitney U test 
was used to compare graded outcomes and continuous dat.'1 
between groups. The correlation coefficients (1") given arc 
Spe:mnan's. P "" 0.05 (two-sided) was considered the limit of 
Significance. 
RESULTS 
Of the 130 patients sent questionnaires, 106 
(82%) responded (mean age 59 years, range 35 to 
84); 12 men did not want to answer the questions 
because of privacy reasons and another 12 did not 
return the questionnaire, even after a second mail-
ing. 
From the questionnaire data, it appeared that at 
the first consultation, 44% reported painful erec-
tions, 97% penile curvature, and 21% ED. Symp-
toms had been present for a median duration of 6 
months (mean II, range 1 to 72). Trauma to the 
penis was reported by 19% of the patients, and 36% 
had Dupuytren's disease. Twenty-two percent of 
the patients had previously been treated unsuc-
cessfully (5 patients with vitamin E, 10 with corti-
costeroids, 1 with verapamil, and 6 had undergone 
surgical correction of the penile deformity). At the 
time of RT, about one third of patients reported 
using concomitant medication known to possibly 
affect sexual functioning (eg, antihypertensive or 
antidepressant agents); 40% smoked an average of 
15 cigarettes daily (range 3 to 25). 
Of the patients with pain before RT, 69% re-
ported that it had diminished; 29% also experi-
enced a decrease in penile curvature. Of the pa-
tients with ED before RT, 13% reported thar their 
erections had improved after RT; 40% had a re-
sponse within 6 weeks, 32% within 3 months, and 
28% after 3 months. Eleven percent reported dis-
comfort during RT (mostly dysuria). Finally, 24% 
had undergone surgery because of persisting se-
vere penile curvature after RT. At the time of the 
questionnaire Ouly 1998), 53% used medication 
(known to pOSSibly affect sexual functioning), al-
most twice as high as the percentage before RT 
(29%; P <0.000 I). Thirty-one percent of patients 
smoked (mean 15 Cigarettes daily, range 3 to 30), 
Significantly less than before RT (40%; P = 
0.006). 
SEXUAL FUNCTrON 
Patients' sexual desire and the Significance of sex 
during the past 4 weeks is reponed in Table 1. The 
frequency of spontaneous erections and difficulty 
in getting and maintaining an erection are reported 
in Tables 11 and Ill, respectively. The rigidity of the 
erections is summarized in Table IV. All these vari-
ables were correlated with age: the older the pa-
tient, the lower the sexual desire (r = -0.28, P 
<0.01), the less Significance attributed to sex (r = 
-0.18, P = 0.08), the lower the frequency of 
spontaneous erections (r = -0.41, P <0.001), 
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TABLE IH. Difficulty in getting and 
maintaining an erection in the past 4 weeks 
No 
Did you have difficulty in 33 (49) 
getting an erection? 
(n == 67) 
Did you have dirficulty 26 (39) 
in maintaining an 
erection? (n "" 67) 
Sometimes Always 
21 (31) 13(20) 
26 (39) 15 (22) 
the less satisfaction with sexual life (r = -0.21, 
P <0.05), and the more difficult it was to achieve 
(r = +0.37. P <0.01) and maintain (r = 
+0.35, P <0.01) an erection. Ninety~two perct:nt 
of patients before and 72% after RT were sexually 
active CP = 0.002). After RT, 26 patients were not 
se .. "uaUy active because of various reasons: lack of 
erections Cn = 12), absence of se.'Cual desire (n = 
9), absence of sexual partner Cn = 1), absence of 
sexual desire in the parmer Cn = 2), or other rea-
sons Cn = 7). After RT treatment, no decrease in 
sexual interest, activity, or pleasure occurred in 
62%,33%, and 51% of patients, respectively. A de-
crease in sexual interest, activity, and pleasure also 
correlated strongly with increasing age. Overall. 
49% of patients reported not being satisfied with 
their current sexual life, 25% were somewhat sat-
isfied. and 26% were (very) much satisfied. 
At the time of the questionnaire (before Viagra 
was introduced in The Netherlands). only 13 pa-
tients were receiving ED treatment: 5 received in-
tracavemosal injections, 3 used a vacuum device, 
and in 5 patients the treatment was not specified. 
COMMENT 
PD remains a mysterious disease. Epidemiologic 
studies have shown a threefold increase in PD 
among patients with previous genital and perineal 
trauma.5 Also, the association with Dupuytren's 
contractures has been reported,1.5 although at a 
percentage lower than in our patients (about 20% 
versus our 36%). RT has been used previously with 
good results.6- 8 The sexual function in patients 
irradiated for PD has never been thoroughly stud-
ied. Usually only one question was asked immedi-
ately after treatment: has there been an improve-
ment in sexual activity or in erectile function?6.7 
Sexual dysfunction in patients with PD may be due 
to severe angulation, pain, or ED. The latter is at-
tributed to veno-occlusive impairment.9 ,lO Before 
RT, 21% of our patients reported ED: a similar per-
centage has been reported by patients undergOing 
surgery.9 In our patients, erectile function im-
proved in only 13% after RT, but penile pain di-
minished in twO thirds of patients and penile cur-
vature decreased in about 30%. Some reports have 
stated that PD is self-limiting in 50% of untreated 
patients and symptoms disappear spontaneously 
within 18 months.1U2 It is understandable that 
men who desire sexual activity and experience pe-
nile discomfort do not want to wait such a long 
period. For those men, RT is a serious treatment 
option, since 69% of our patients experienced pain 
relief within 3 months after RT, considerably 
shorter than the pOSSible normal evolution of (he 
disease. ll ,12 
We understand that a group of control patients 
who did not undergo RT would have been helpful 
for comparison. A control group was not possible 
in our study, since all patients were referred to us 
for immediate treatment, when no spontaneous 
improvements had occurred after a 6~month obser-
vation period. We do not have data on the sexual 
function of our patients immediately after RT treat-
ment. We mailed our questionnaire at an average 
of9 years after RT; patients were also 9 years older. 
Sixty-eight percent of patients expressed sexual de-
sire and for 62%;5ex was (very) much significant. 
Sexual activity before RT was higher, but this was 
almost 10 years earlier. Thirty-six percent of pa-
tients never had spontaneous erections; 51% some-
times or always had difficulty in getting an erec-
tion, and 61 % had difficulty in maintaining an 
erection. Rigidity was enough for sexual activiry in 
only 46% of patients who were sexually active. Al-
though of older age (ie, 59 years old), 72% of pa-
tients were sexually active, comparable with the 
data from the Massachusetts Male Aging Study.13 
The decrease in sexual interest, activity, and plea-
sure after RT treatment (compared with before RT) 
may be explained by the increased age. Other risk 
factors (eg, medication and disease) could also play 
a role; unfortunately, detailed information was 
lacking. 
When patients were divided into three age 
groups (younger than 49, 50 to 69, and older than 
69 years), all aspects of sexuality correlated 
strongly with age. In the older group, incidence of 
problems in getting and maintaining erections and 
less sexual desire, satisfaction, frequency, and ri-
gidity of spontaneous erections and erections dur-
ing se),:ual activity was Significantly higher. Pa-
tients indicated a high satisfaction rate after RT 
regarding penile pain, but almost 50% were dissat-
isfied with their current sexual life. It is of interest 
that our patientS, although they were irradiated for 
PD some 9 years earlier, reported the same prob-
lems concerning sexual function as patients of the 
same age without earlier treatment for PD.13 About 
50% of patients reported problems in getting or 
maintaining an erection, but two thirds did.not use 
any treatment modality. 
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TABLE IV. Rigidity of spontaneous erections and erections during sexual activity in the past 4 
weeks 
How rigid were spontaneous erections? (n 59) 
How rigid were erections during sexual activity? (n '" 68) 
CONCLUSIONS 
The results of our study demonstrate that the 
principal advantage of RT in patients with PD is a 
decrease in pain and discomfort. RT is less effective 
in improving erectile function. Problems v..ith se.x-
ual functioning seem to be related to patient age 
rather than PD. 
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the Mas~chusetts Male Aging Study. ] Urol lSI: 54-61, 
1994. 
EDITORIAL COMMENT 
The authors report a series of patients who underwent RT 
for PD. Although studies in the 1980s suggested some value to 
RT for the pain associated with PO, its beneficial e£fects on 
penile angulation and plaque have been reported only mrcly. I 
Similarly, studies by Gelbard et a/.2 investigating thc natumJ 
Not at All 
1 (2) 
3 (4) 
Somewhat 
5 (8) 
0(0) 
Half 
26 (44) 
34 [50) 
Rigid 
20 (34) 
18 (27) 
Very Rigid 
7 (12) 
13 [19) 
history of PO demonsml[e convincingly t1ut penile pain re-
solves spontaneously in most patients with stable PD. 
A report by Hall et aU in 1995 Clrefully examined the re-
~;1l1ts of RT on the corpus Clvemosum smooth muscle tissue 
after 1200 cGyof external beam RT. This small dose produced 
slgnifiClnt abnormalities and radiation change in the corpus 
cavernosum tissue. Clinical changes included woody indum-
lion, an abnormal nocturnal penile tumescence mOnitoring 
study, and a pharmacocavemosometry study demon5trnting 
probable new onset of diffuse corporeal veno-occlusive dys-
function. Attempted treatment v.ith pharmacologic injection 
thernpy was unsuccessful, and penile prosthesis implantation, 
although successful, was quite difficult. Careful histologiC 
:malysis of the c""{cised corpus Clvemosum smooth muscle 
tissue revealed extensive fibrosis in anerlal vasculopathy. 
There was a significant loss of trabecular smooth muscle, with 
desmin immunohistochemical staining revealing extensive fi-
brosis. 
Since studies of the natuml history of PO have documented 
resolution of pain in the vast majority of patients without 
invasive therapy and because RT prOvides little thernpeutic 
benefit for patients complaining of penile curvature, plaque, 
::md induration, RT must be carefully considered before sug-
gesting it as an alternative for the trcaunent of PD. More im-
portantly, external beam RT appears to produce Significant 
corpus cavemosum smooth muscle fibrosis, which results in 
aggravation of the ED frequently assocbted with PO and, per-
haps, a new onset of severe vena-occlusive ED, and substantial 
arteriopathy. With newer, less invasive, alternatives such as 
vempamil plaque injection and anti-inflammatory agents, RT 
should be used only rarely and with Clreful counseling of the 
patient before treatment to inform him of the possibility of 
inadequate trcaunent of penile pain and subsequent ED. 
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REPLY BY THE AUTHORS 
The principal advantage of RT in PO is a decrease in 
penile pain and discomfort; we were surprised that 29% of 
Chapter 6 49 
our patients also reported an improvement in penile angu-
lation. Only 24% of our patients underwent surgery after 
RT because of persisting severe penile CUrv:lturc. We advo-
cate RT only if the penile pain isscvcrc and docs notspon-
tancously improve after a 6-month period of observation. 
It is true that PO can be self-limiting, but, as reponed by 
Devine and Horton,! this occurs in only 50% of patients 
within 18 months. Given the distressing nature of the 
symptoms, many patients do not wish to wail so long. 
Seventy-two percent of our patients reported a decrease in 
penile pain within 3 months after RT. 
No worsening of ED \V;l$ reponed after RT in our study_ 
On the contmry, 13% of our patients had improved cree-
lions. We therefore do not believe that RT results in [he 
aggravation of the ED frequently associated with PD. 
The problems with PD remain itS mysterious etiology, 
the limited treatment alternatives, and the lack of random-
ized trials. 
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Abstract 
This paper evaluates current sexual functioning in patients with prostate cancer awaiting 
treatment. One-hundred-fifty-eight patients filled out a IS-item questionnaire regarding 
current sexual functioning. Median age was 67 years. Sixty per cent reported to have 
spontaneous erections at least once a week with a good firnmess in 37%. During sexual 
activity, 35% reported no difficulty in getting erections and 33% in maintaining an erection. 
After diagnosis, all patients reported a decrease in sexual interest, activity and pleasure. 
Diagnosis of prostate cancer does have an impact on sexual functioning, therefore sexual 
counseling prior to treatment is advised. 
Introduction 
Prostate cancer (PC) has become the most frequent malignancy in men in Western countries. 
Over recent years the number of diagnosed patients has increased dramatically because of 
routine prostate specific antigen (PSA) tests and tbe awareness of possibility of cure of early 
disease, witb a 5-year relative survival rate of98% (parker, Tong, Bolden, & Wingo, 1996). 
Standard treatments in The Netberlands comprise radical prostatectomy (RP), external 
beam radiotberapy (RT) or observation. Randomized trials are in progress to investigate 
whether RP and RT are superior to observation for long-term survival rates. Treatment 
choice is often determined by tumor staging, patient's age and co-morbidity, urologist's and 
patient's preferences. Patient's health related quality of life including sexual functioning is 
very important in decision making. As reported by Singer, Tasch, Stocking, Rubin, Siegler, 
& Weichselbaum (1991) some men may choose a treatment with lower long-term survival to 
increase their chance of remaining sexually potent. The occurrence of erectile dysfunction 
(ED) after RP varies in tbe literature from 30% witb sparing botb neurovascular bundles 
(Catalona & Bigg, 1990) to 50% when only one bundle is spared (Walsh, Epstein, & Lowe, 
1987) and reaches 98% in non-nerve-sparing techniques (Lim, Brandon, Fiedler, Brickman, 
Boyer, Raub, & Soloway, 1995). After external RT, ED occurs in up to 77% of patients 
(Mantz. Song, Farhangi, Nautiyal, Awan, Ignacio, Weichselbaum, & Vijayakumar, 1997; 
McCammon, Kohn, Mall, & Schellhammer, 1999; Shrader-Bogen, Kjellberg, McPherson, 
& Murray, 1997; Turner, Adams, Bull, & Berry, 1999). 
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However, time is important after RT: erectile function continues to decline after 12 months 
and reaches a plateau after 24 months (ED in 38% and 59%, respectively) (Mantz, Song, 
Farhangi, Nautiyal, Awan, Ignacio, Weichselbaum, & Vijayakumar, 1997; Tumer, Adams, 
Bull, & Berry, 1999), 
The impact of treatment on potency is difficult to determine unless a baseline, pretreatment 
assessment of erectile function is included. The present study was carried out to detennine 
pre-treatment sexual functioning in PC-patients awaiting treatment and to evaluate whether 
the diagnosis of PC had an impact on sexual functioning. Furthermore these data were 
collected to be used for comparison one and me years later in the same patients following 
PC-treatment. 
Patients and Methods 
In the period 1996-1998 166 patients with localized PC were referred to our hospital for 
treatment Eighty-five subjects were to be treated with RP and 81 with RT, Treatment choice 
had been previously determined by urologist's and patient's preferences. All subjects were 
asked to fiU out at home a I5-item questionnaire with items regarding various aspects of 
sexual functioning of the past 'hvo weeks. The questions referred to sexual interest. pleasure 
and activity and problems with getting erections following PC diagnosis (Appendix A). The 
questionnaire was adapted from a previously used version (Incrocci. Hop. & Slob, 1996; 
Slob, Blom, & van der Werfften Bosch, 1990). The response rate was 91 %: 158 out of 166 
patients accepted to fill out the questionnaire. 
Statistical methods 
The statistical analysis was primarily descriptive, Differences between the RP and RT 
patients in the answers to the different questions and in the distribution of age were tested 
with the Kruskal-Wallis test and logistic regression, 
Results 
Median time between diagnosis and survey was 6 weeks (range 4-9 weeks), Patients' 
characteristics are stunmarized in Table 1. Median age was 67 years (range 50-80 years). 
Co-morbidity (diabetes and/or cardiovascular history) was reported in 21 % of the patients. 
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Sixty-five patients (41%) indicated to have (very) much sexual desire. Sex was (very) 
important to 124 men (78%). Sixty per cent reported spontaneous erections (= outside sexual 
activity), at least once a week. Firmness of these erections was good in 57 subjects (37%). 
Fifty-five patients (35%) reported no difficulty in getting and 52 (33%) no difficulty in 
maintaining an erection. For 56 patients (35%) these erections were finn enough for sexual 
activity (mastrnbation or intercourse). Overall satisfaction with sexual life was (very) high in 
84 patients (53%). We found no statistically significant differences in sexual fimctioning 
between subjects with or without co-morbidity (all p values> 0.1). 
Impact of cancer diagnosis 
Receiving the diagnosis of PC (4-9 weeks earlier) had caused an important decrease in 
sexual activity in 31 patients (20%), in sexual interest in 12 patients (15%), in sexual 
pleasure in 20 patients (12%) and there was an increase in problems with getting an erection 
in 16 patients (10%). Before diagnosis 105 subjects (66%) were sexually active; alier 
diagnosis, over the past two weeks, 88 patients (56%) were sexually active; this difference is 
highly statistically significant (p=0.008). The reason of not being sexually active was ED in 
only 15 men (10%); other reasons were absence of partner or no sexual desire in the partner. 
Differences between RP and RT patients 
The choice of treatment was not random, but determined by urologist's and patient's 
preference. As can be seen in Table I, RP patients were significantly younger than RT 
patients (median age 63 vs 69 years), PSA was significantly lower (4 ~gll vs 8 ~gIl) and 
there were less cardiovascular diseases (14% vs 23%). To make comparisons in ED rates 
after treatment one should be aware of the differences between these two groups of patients. 
RP and RT patients differed in their current level of sexual activity (77% versus 57%, 
respectively, p=O.OI). About half of the RP patients reported nO problems in getting (45%) 
or maintaining an erection (42%) versus only a quarter of the RT patients (25% and 26% 
respectively), a statistically significant difference (p=0.01). More RP patients (60%) than RT 
patients (46%) indicated high or very high overall satisfaction with sexual life (p=0.004). A 
logistic regression analysis with adjustment for age and the following independent variables: 
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sexual desire, spontaneous erections, sexual activity, significance of sex and satisfaction 
with sexual life, showed no statistically significant differences between the RP and RT 
patients, except for satisfaction with sexual life (lower in RT patients than in RP patients, 
p~0.04). 
Discussion 
A very commonly ignored aspect of PC therapy is the impact on sexual activity and sexual 
functioning (McCanunon, Kolm, Main, & Scheilhanuner, 1999; Ofman, 1995). Although the 
use of advanced surgical techniques as the nerve-sparing RP and the introduction of 
conformal RT, sexual functioning after PC treatment remains a concern, 
In order to carefully evaluate the impact of PC diagnosis and treatment on sexual life it is 
necessary to assess sexual functioning prior to treatment (Stock, Stone, & Iannuzzi, 1996; 
Zinreich, Derogatis, HelpS!, Auvil, Piantadosi, & Order, 1990). Many published studies used 
retrospective assessments of sexual functioning prior to treatment (Lim, Brandon,. Fiedler, 
Brickman, Boyer, Raub, & Soloway, 1995; Mantz, Song, Farhangi, Nautiyal, Awan, 
Ignacio, Weichselbaum, & Vijayalannar, 1997; Shrader-Bogen, Kjellberg, McPherson, & 
Murray, 1997). Some studies evaluated pre-treatment sexual functioning with a prospective 
design (Litwin, Flanders, Pasta, Stoddard, Lubeck, & Henning, 1999; Stock, Stone, & 
Iannuzzi, 1996; Tumer, Adams, Bull, & Berry, 1999). Often PC patients are impotent before 
treatment. Therefore, assessment of this condition is necessary to predict sexual functioning 
after therapy (Robinson, Dufour, & Fung, 1997; Stock, Stone, & Iannuzzi, 1996; Zinreich, 
Derogatis, Helpst, Auvil, Piantadosi, & Order, 1990). Preservation of potency is more likely 
to occur if there is no or minimal impairment before treatment (Tumer, Adams, Bull, & 
Berry, 1999). 
Of the 600 articles reviewed by Robinson, Dufour & Fung (1997) on ED in men after PC 
treatment only 40 (15%) comprised papers in which pre4Teatment erectile functioning was 
assessed. They stated that this is the most important criterion to provide meaningful end 
comparisons of ED after RP or RT. The lack of consistency in definitions of potency makes 
it difficult to compare the results from different studies. 
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In our study, potency was defined as the ability to achieve erections sufficient for sexual 
activity (masturbation or intercourse). Ideally, besides the questionnaire and in order to 
possibly differentiate between psychological and organic erectile dysfunction, we would 
have used also objective measurements as penile Doppler ultrasonography, Visual Sexual 
Stimulation or Nocturnal Penile Tumescence recording with the Rigiscan, but we felt this to 
be too time consuming and too cumbersome for our patients. 
Because of the multifactorial nature of sexual dysfunction not only erectile function but 
also libido, satisfaction with sexual life and interest in sex should be assessed (Schaver, 
1993). Therefore, we adapted a IS-item questionnaire regarding many aspects of sexuality, 
routinely applied to all new ED patients (Incrocci, Hop, & Slob, 1996; Slob, Blom, & van 
der Werfften Bosch, 1990). More recently an international questionnaire, also validated in 
our country, the International Index of Erectile Function (liEF) has been introduced (Rosen, 
Riley, Wagner, Osterloh, Kirkpatrick, & Mishra, 1997), but unfortunately this was not yet 
available at the moment of our study. 
Sexual dysfunction in PC patients can be due to different factors such as age, medical 
therapy, co-morbidity, use of tobacco, alcohol, previous pelvic surgery or the prostate 
carcinoma itself (Helgason, Adolfsson, Dickman, Arver, Fredrikson, & Steineck, 1997; 
Melman & Gingell, 1999). Helgason, Adolfsson, Dickman, Arver, Fredrikson, & Steineck 
(1999) reported ED in 57% of patients with PC after RT and 53% in the not-treated men, 
assessed at 1.5-2.5 years after diagnosis. This suggests that PC itself was associated with an 
increased risk of sexual impairment. 
In our study the diagnosis PC resulted in decreased sexual activity. Although sexual 
functioning prior to diagnosis was assessed retrospectively (it is actually impossible to do 
tlus prospectively), the possibility of recall bias was rather limited because of the short time 
between diagnosis and survey (median 6 weeks). 
The prostate gland itself is not essential for normal sexual function but most men express 
al1.xiety after diagnosis of PC thinking of losing erectile capacity because of treatment 
(Schover, 1993). Fear of death and worries about family can also playa role in impairing 
sexual functioning when men are told they have cancer. 
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We are aware that a control group of patients without PC would have been interesting, but 
this was not possible in our case. Of our patients only 35% expressed no problem "With 
getting or maintaining an erection. Reports on the Dutch population reveal that in men 60-69 
years and 70 years and older the percentage of problems in getting an erection is 22% and 
38%, respectively (Meuleman, Donkers, & Kiemeney, 2000), Thus, the incidence of ED in a 
normal population seems to be lower than in our PC patients, In the Meuleman et aL (2000) 
study 35% of subjects 60-69 years and in 53% in 70-79 years were satisfied with their sexual 
life; these figures arc similar to our PC-patients data, 
Bosch, Groeneveld, Bohnen, Prins, & Hop (1999) reported an incidence of ED in 49% of 
men 70-74 years, in a community-based sample of 1661 men. This percentage is much lower 
than in the present study (65%), 
Forty-one per cent of our patients expressed a high level of sexual desire and 78% 
considered sex very important. Helgason, Adolfsson, Dickman, Arver, Fredrikson, 
G6thberg, & Steineck (1996) reported similar percentages in men without PC: 83% stated 
that sex was (very) important and 76% of men aged 60-69 years were potent 
Before diagnosis, 66% of our patients were sexually active. These percentages are similar 
to those of Janus & Janus (1993) who reported that 69% of212 men 65 years and older had 
weekly sexual activity, and of Brecher (1984) who reported that 79% of 598 men 70 years 
and older were sexually active. 
Diabetes and hypertension are significantly associated with ED, as well certain 
medications and the use of tobacco (Feldman, Goldstein, Hatzichristou, Krane, & McKinJay, 
1994). We found no statistically significant difference regarding sexual functioning in 
patients with or without co-morbidity, possibly because of the small numbers (ouly 21% of 
patients with co-morbidity). None of our patients were on hormonal therapy; use of tobacco 
or alcohol was not always reported. 
A significant difference in age was found between RP and RT patients, similar to earlier 
published studies (Lim, Brandon, Fiedler, Brickman, Boyer, Raub, & Soloway, 1995; 
McCammon, Kohn, Main, & Schellbammer, 1999; Shrader-Bogen, Kjellberg, McPherson, 
& Murray, 1997), Age difference is the main reason of all differences encountered in sexnal 
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functioning, therefore the differences in sexual functioning between patients undergoing RT 
or RP are mostly related to the doctor's preference for surgical treatment in younger men. 
We are aware of the limited value of these mainly descriptive data, but such information is 
useful to make comparisons of treatment morbidity. Currently, data are been collected on 
sexual functioning in the same patients, one and two years after therapy_ 
Conclusions 
There is a decrease in all aspects of sexual functioning after the diagnosis of PC. Because of 
the impact of diagnosis and treatment of PC on sexual function,. patients with PC may 
benefit profoundly from sexual counseling before (and presumably following) treatment. 
Baseline data on sexual functioning prior to treatment are relevant for later comparison with 
data after treatment and to detect treatment related morbidity. 
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Table 1. Characteristics ofn=15S patients with localized prostate cancer awaiting treatment, 
either radical prostatectomy (RP) or external beam radiotherapy (RT) 
Total (n=15S) RP(n=77) RT(n=Sl) 
Median age (range) years 67 (50-SO) 63' (50-73) 69 (55-SO) 
n(%) n (%) n (%) 
Diabetes Mellitus 5 (3) 1 (1) 4 (5) 
Cardiovascular disease 30 (IS) 11 (14) 19 (23) 
TNM classification: 
T1 20 (13) 11 (14) 9 (11) 
T2 97 (61) 52 (6S) 45 (56) 
T3 34 (22) 14 (IS) 20 (25) 
T4 3 (2) 0(0) 3 (4) 
unlmown 4 (2) 0(0) 4 (4) 
NO 127 (SO) 46 (60) Sl (100) 
NX 31 (20) 31 (40) 0(0) 
MO 15S (100) 77 (100) Sl (100) 
Differentiation grade: 
Gl (good) 78 (49) 40 (52) 3S (47) 
G2 (moderately) 60 (3S) 29 (3S) 31 (3S) 
G3 (poor) 19 (12) S (10) 11 (14) 
unknown 1 (1) 0(0) 1 (1) 
Median PSA (range) 1'g/1 9(1-59) 4' (1-30) S (1-59) 
* p<O.OOOl versus RT patients 
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Appendix A: Questionnaire on sexual functioning 
1. How much sexual desire (sexual thoughts or feeJings) did you have in the past 2 weeks? 
None at all 
Some 
Moderately 
Quite a bit 
Very much 
2. How often did you have a spontaneous erection (partly or complete, not during sexual 
activity) at night or in the morning in the past 2 weeks? 
Never (skip next question) 
About once 
More than once 
About once a day 
More than once a day 
3. How would you rate the quality of those spontaneous night or morning erections? 
1 
rather soft 
2 
4. How important is sex to you? 
Very unimportant 
Unimportant 
Somewhat important 
Important 
Very important 
3 4 5 
half softlhalfhard very fum 
5. How satisfied are you, in general, with your current sexual life? 
Very satisfied 
Satisfied 
Somewhat satisfied 
Unsatisfied 
Very unsatisfied 
6. Were you sexually active (i.e. masturbation or intercourse) before you were informed to 
have prostate cancer? 
Yes, continue with question 7 
No, skip questions 7-10 
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7. Since you were informed to have prostate cancer, were you less interested in sex than 
before your illness? 
Not at all 
A little 
Quite a bit 
Very much 
8. Since you were informed to have prostate cancer, were you less sexually active than 
before your illness? 
>!ot at all 
A little 
Quite a bit 
Very much 
9. Since you were informed to have prostate cancer, did you have more difficulty in getting 
or maintaining an erection than before your illness? 
Not at all 
A little 
Quite a bit 
Very much 
10. Since you were informed to have prostate cancer, was sex less enjoyable for you than 
before your illness? 
Not at all 
A little 
Quite a bit 
Very much 
11. Were you sexually active (i.e. masturbation or intercourse) in the past 2 weeks? 
Yes, go to questions 13-15 
1\0, go to question 12, skip questions 13-15 
12. I was not sexually active in the past 2 weeks because .... 
I had no sexual desire 
I do not have a partner 
My partner did not have sexual desire 
I could not get an erection 
Ofuerwise, ", ......... (please describe) 
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13. Did you have difficulty in getting an erection in the past 2 weeks? 
Yes, (ahnost) always 
Yes, sometimes 
No, (ahnost) never 
14. Did you have difficulty in maintaining an erection in the past 2 weeks? 
Yes, (ahnost) always 
Yes,sometimes 
No, (ahnost) never 
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15. How would you rate the quality of your erections during sexual activity in the past 2 
weeks? 
1 
rather soft 
234 
half softlhalfhard 
5 
very finn 
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Abstract 
Prostate cancer has become the most frequent malignancy in older men in Western countries. 
With the improvement of treatment efficacy sexual functioning has become more important. 
In the current review we discussed the various methods used for the evaluation of sexual 
dysfunction, the definition of potency and the etiology of erectile dysfunction after external 
beam radiotherapy and brachytherapy. The literature has been summarized and comparative 
studies of radiation and surgery have been briefly surveyed. 
Percentages of erectile dysfunction following radiation reported in the literature vary 
enormously. from 6 to 84% after external beam radiotherapy to 0-51% after modem 
brachytherapy techniques. Most of the studies are retrospective. the definition of erectile 
dysfunction is not always clear, often only one question about sexual functioning is asked. 
Time since radiation is very relevant, one should at least wait 18-24 months before drawing 
final conclusions on impotence occurrence. The most likely cause of erectile dysfunction after 
radiation for prostate cancer is a vascular damage although the etiology is not completely 
understood. Sexual desire, satisfaction, frequency of intercourse should also be assessed. 
Patients should be offered sexual counseling and informed about the availability of effective 
treatments for erectile dysfunction such as sildenafil, intracavemosal injection and vacuum 
devices. 
Key-words: prostate cancer, radiation, sexual function, sexual dysfunction 
Introduction 
Prostate cancer (PC) has become the most frequent malignancy in men in Western countries. 
In 1996, 6539 new cases were diagnosed in the Netherlands with an incidence of 87.7 per 
100.000 persons (Netherlands Cancer Registry, 1998). Over recent years the number of 
diagnosed patients has dramatically increased because of routine prostate specific antigen 
(PSA) testing and the awareness of potential for early disease cure, with a 5-year survival rate 
of 98% (1). A commonly ignored aspect is the impact of PC-therapy on sexual activi!y and 
sexual functioning (2,3). Irrespective of the use of advanced surgical techniques, as the nerve-
sparing radical prostatectomy and the introduction of 3-Dimensioual Conformal Radiotherapy 
(3D-CRT), sexual functioning after PC treatment remains problematic for many patients. 
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Standard treatment options for PC comprise radical prostatectomy (RP), external beam 
radiotberapy (ERT) or observation. In recent years, in a number of institutions, brachytberapy 
(BT) has become tbe preferred treatment in small tumors or in combination witb ERT for 
locally advanced tumors. The choice of treatment is usually determined not only by tumor 
staging, patient's age and comorbidity, but also by urologist's and patient's preferences. 
Patients witb higher-staged, i.e. T2b-T4, PSA >10 nglml, less differentiated tumors, are 
frequently offered ERT in combination witb hormonal tberapy (4). Younger patients, i.e. less 
than 70 years, with smaller tumors and lower PSA are offered RP or BT, if tbe medical 
condition is not compromised by a cardiovascular or pulmonary history. Wait and see is 
mainly offered to older patients (> 80 years) witb low-staged tumors. We believe tbat 
patient's healtb-related quality oflife (QoL), including sexual functioning, shonld also be an 
important factor in decision making. In fact, when given the choice, men might choose a 
treatment with lower long-term overall survival, if it would increase their chances of 
remaining sexually potent (5) and enjoying an active sexual life. 
The purpose of this paper is to present an overview of tbe literature dealing witb sexual and 
erectile dysfunction (ED) after ERT andlor BT. Abstracts-only or papers dealing witb PC 
patients with metastatic disease, or on hormonal therapy, have not been included in this 
review. First, we will discuss the various methods used of evaluating and defining ED. Then 
tbe etiology of ED following ERT and BT will be reviewed. The literature will be 
summarized regarding ERT, BT and sexual functioning. Also papers dealing witb sexual 
dysfunction otber tban ED will be discussed. Finally, comparative studies ofERT and RP will 
be briefly surveyed. We end this review paper with the main conclusions and 
recommendations for radiation oncologists. 
Evaluating Erectile Dysfunction: Methodology and Difficulties 
Already in 1965 concerns witb sexual (dys)functioning in patients following ERT for PC 
were expressed (6,7). In 1977 Perez et aI. mentioned impotence as a «vexing complication" 
(8). Most papers focussed on treatment outcome, and bowel and urinary toxicity; sexual 
function was only marginally mentioned. The first paper reporting extensively and 
specifically on potency after radiation treatment appeared in 1988 (9). The most practical and 
quickest way of evaluation of ED is the use of self-administered questionnaires. 
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The problem, however, is the variability of the questionnaires used in the published papers, 
i.e. some validated, some not. Only recently an international questionnaire, the International 
Index of Erectile Function (lIEF) has been validated in many countries and offers the 
possibility to make comparisons between different studies (10). However, to our knowledge, 
it has not been used in the evaluation of ED after radiation for PC. 
In most papers from the 70's and 80's no methodological data was reported, that is only the 
rate of potency/impotence was mentioned (6-9,11-60). 
In many of the published questionnaires on sexual function the questions were often limited 
to 2-6 items and were part of a more general questionnaire on toxicity of radiation treatment 
and/or on QoL in general (2,29,31,40,43,48,61-81). In the majority of cases the questionnaires 
as a whole were not included in the paper but, instead, just a few questions were listed 
(62,63,68,69,72,76,79,81-95). In some papers, fortunately, the complete questionnaire was 
presented as a table or as an appendix, which offered a more transparent description of the 
methodology used (2,64,67,75,80,96-98). 
In summary, beyond the question on erectile function, the questionnaires used offered 
limited information on sexuality. There are, however, a few exceptions (9,85-88,91,96,99) 
where items such as desire, ejaculation, satisfaction with sexual life, frequency of 
spontaneous erections and frequency of intercourse were also asked. 
Examples of extensive questionnaires are the Radiumhemmet scale of sexual functioning 
(87,91), the Derogatis Interview for Sexual Functioning (DISF) (100), the Brief Sexual 
Function Inventory (101) and the Psychosocial Adjustment to TIIness Scale (PAIS) (102). 
Other validated instruments were seldomly used (71,73,75,77,78,80,103-105). 
Definition of Potency 
Another significant aspect in studies dealing with ED after ERT for PC is the lack of a 
definition for potency and/or impotence (6-8,11-16,18-20,22,23,25-33,35-7,39,41,42,46,47, 
52,53,56-58,61-63,66,67,69,71,72,74,75, 77 -80,84,90,93-95,97,104-107). 
The National Institute of Health (Nlli) Consensus on ED defined impotence as: the consistent 
inability to attain and maintain a penile erection sufficient to pemrit satisfactory sexual 
intercourse (108). One could argue, however, that such a definition is strictly relevant in the 
presence of a willing partner. 
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A definition of (im)potence which is similar to the one advocated by the NllI but with some 
variations has been used by many authors in ERT and BT studies (17,21,24,34,38,40,43-
45,51,54,55,59,60,64,68,70,83,85,87,89,92,96,99). 
More detailed and complex definitions had been also advocated by other authors (2,48-
50,76,82,86,88,89,91,98,109). A potency graded scale has also been used (48,76,89,98). 
McCannnon ef al. were the first to define potency as physician's documented erections (2) 
while Banker used both frequency of intercourse and rigidity of erections as a parameter for 
potency (9). 
Potency does not only mean getting an erection but also the ability to maintain it. This latter 
aspect is very often ignored by the investigators or not discussed. Because ED is more than 
just a non-functional penis, other relevant sexual factors such as also libido, satisfaction "With 
sexual life and interest in sex should also be assessed (110). Quality of erections, i.e. firmness 
of erections, is also very important. Knowledge about the presence of spontaneous erections 
or the occurrence of moming/night erections is necessary to differentiate between a (mainly) 
organic or a (mainly) psychological etiology. 
One should be aware that in many irradiated patients psychological factors also playa role, 
albeit somewhat less important than the organic ones. There is a need to differentiate between 
having ED and not being sexually active. The latter is often due to factors other than erectile 
insufficiency, e.g. absence of a "willing" partner or lack of interest in sex in the man. 
Ejaculatory disturbances could also play a role, especially in patients irradiated for PC; 
sometimes older men cannot differentiate between being impotent and not being able to 
ejaculate. For this reason more complete questionnaires are recommended. 
In conclusion, a simple, unequivocal definition of "potency" is lacking. Usually, the 
following questions have not been addressed properly: What is a good erection, the one 
assessed by the patient or by the physician? Is it necessary to use a complicated definition or 
is it sufficient to refer to the standard definition of the Nlli? Is only the presence of an 
erection important or also the rigidity of these erections which allows sexual activity? We feel 
that the standard definition of (im)potence advocated by the NllI is appropriate and should be 
used, in order to make comparisons between different studies possible. Moreover. if a patient 
defines his ovm erection as sufficient for sexual intercourse or masturbation he should be 
considered potent. Nevertheless, for study purposes on potency in general, we believe that a 
more extensive evaluation of patients' sexuality should be carried out. Is the patient sexually 
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active, does he have a sexual partner, is his partner interested in sex with him, does he have 
premature ejaculatio~ does he have sexual desire. These and other sexuality items are 
relevant in the assessment of post-radiation (dys)function. 
Etiology of Post-Radiation Erectile Dysfunction 
To our knowledge only three papers with proper methodology have been published on the 
etiology of ED after ERT (111-113). 
Goldstein et al. performed objective tests of erectile functioning in 23 patients, 6-60 months 
after ERT (30-70 Gy), including Nocturnal Penile Tumescence (NPT) tests, bnlbo-cavernosus 
reflex latency, perineal electromiography, penile Doppler nltrasonography, and endocrine 
screening (blood levels of luteinizing hormone, prolactin and testosterone) (111). Before 
ERT, 15 patients were considered potent: erections sufficiently rigid for vaginal penetration 
and sustained until ejaculation, with regular coitus several times per month and well sustained 
periods of increases in penile circumference during NPT testing. Twelve patients whose 
erectile capacity worsened after ERr had normal blood hormone levels, and normal 
neurological tests. Vascular evaluation by penile Doppler was abnormal in all patients with 
altered erectile function after ERT. A selective pudendal arteriography performed in 2 
patients revealed occlusive vascular disease within the pelvic radiation field (bilateral 
narrowing of the intemal iliac arteries and tortuosity and occlusions of the internal pudendal 
and penile arteries). 
In conclusion, endocrine data corroborated earlier findings of normal Leydig's cell function 
and testosterone production (8,16,83). Injury to the pelvic nerves could not be identified. The 
vascular abnormalities found could be explained because portions of the internal pudendal 
and penile arteries were inevitably exposed to the majority of the radiation delivered to the 
prostate. The presence of other vascular risk factors (smoking, hypertension) might 
predispose to develop a pelvic vascular insufficiency because of the synergistic effect of 
radiation. Furthermore, patients were also interviewed by a psychologist and feelings of 
anxiety, depression, anger, fear of failure, loss of masculinity were found. Mittal evaluated 
penile blood circulation and its effect on erectile function in 6 patients, before and 6-9 months 
after radiation using Penile Brachial Index (PBI) and Penile Flow Index (PFI) (112). No 
statistically significant difference between pre- and post-radiation values of PBI and PFI 
testing was found. 
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However, evaluation at 6-9 months after radiation is too short to show a possible damage to 
the vessels, and the methods used, nowadays considered obsolete, were possibly not accurate 
to draw conclusions. 
Zelefsky and Eid evaluated 38 patients who became impotent after ERT or 1-125 BT, using 
Duplex ultrasound before and after intracavernosal injection of prostaglandin (113). This 
method assesses the adequacy of penile blood flow and erectile function, structure and 
function of the cavemosal arteries and dorsal veins. Diameter of the arteries before and after 
injection can be used to quantify their distensibility and any increase in diameter of the 
cavernous arteries less than 95% was considered abnormal. A cavemosal dysfunction 
(abnormal cavernosal distensibility with a normal penile peak blood flow) was reported in 
32% and arteriogenic (peak penile blood flow rates less than 25 cc/min) in 63% of the 
patients. Both dysfunctions were present in 3% of patients, neurogenic dysfunction (normal 
distensibility and normal peak blood flow values but poor erectile responses also after 
prostaglandin injection) in 3% of patients. Comorbidity, hormonal manipulation, smoking and 
age had no influence on the type of dysfunction observed. The authors concluded that the 
predominant etiology of radiation-induced impotence was arteriogenic, i.e. due to a disruption 
of the arteriolar system supplying the corporal muscles, although other unlmown factors 
might also playa role (113). Thus, their conclusions corroborated those of Goldstein et al. 
(111). 
In two BT studies mention of possible etiology of post-radiation ED was made (50,96) and 
two other papers studied specifically the dose to the neurovascular bundles in patients treated 
with Palladium-l 03 (Pd-l03) or lodine-125 (1-125) seeds, with or without ERT (114,115). Di 
Biase et al. posrulated that BT -related impotence might be due to excessive radiation dose to 
the neurovascular bundles (114). The authors made a detailed calculation of the dose to these 
regions, which was higher than the prescription dose (for Pd-l03 150-260 Gy, for 1-125200-
325 Gy), but they did not correlate these fi.tldingS with potency data. This was done by 
Merrick et al. in 33 patients who developed ED after BT and in 21 men who remained potent 
following treatment (115). By using the same methodology as Di Biase et aI., they found no 
significant difference in mean dose to the neurovascular bundles between potent and impotent 
men, between the two different isotopes (1-125 versus Pd-103) and with or without 
combination with ERT, after a follow-up time of37 months (115). 
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It should be kept in mind that, because of the inability to visualize the bundles on a planning 
CT, doses had to be estimated and calculations therefore might not be always accurate. 
Incidence of Erectile Dysfunction after External Beam Radiotherapy for Prostate 
Cancer Patients 
Studies published in the 70 's 
To our knowledge, the first two studies on ERT for PC discussing potency were published in 
1965 (6,7). Generally ED rates, albeit in small series, varied reportedly between 6 and 84% 
(11-13,15-17,19,21,22). In two larger studies incidence of ED, determined at 15 months post-
ERT, was between 30-40% (15,17). 
A compilation of the studies published in the 70's can be seen in Table L Unfortunately, 
because of the non-controlled character of most studies. no meaningful conclusions can be 
drawn. Treated patients were also younger (mean age 57-65 years) than we see nowadays for 
ERT treatment, and the percentage of patients potent prior to ERT was often missing except 
for a few studies (12,15,17,22). 
Studies published in the 80's 
In the 80's Megavolt energies using linear accelerators were routinely used and interstitial 
techniques were introduced. Comorbidity was seldom reported, with a few exceptions 
(9,33,35,99); all studies except one (35) reported ED percentages prior to ERT. A summary of 
the studies published in the 80's is presented in Table L 
ED rates ranged from II to 73% (9,26,27,33,35-37,83,84,99). For the first time in the 80's 
sexual (dys)function was assessed prospectively; impotence did not correlate statistically 
significant with testosterone concentration (83,84) and tumor stage did not seem to influence 
incidence of ED (37). 
in general, papers from the 80's did not differ much from those published in the 70's. 
However, there were two exceptions: in 1988 two innovative papers appeared which focussed 
specifically on sexual (dys)function after ERT for PC (9,99) . 
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Banker studied the relationship of potency before and after ERT (9). The author personally 
interviewed patients prior to and 8-12 months after treatment and concluded that men who 
were sexually active before treatment had a good chance ofretaming potency after ERT (9). 
This was the first prospective study focussing on ED following ERT. Van Heeringen et al. 
queried patients on comorbidity factors, smoking habits, partner availability, libido, erections, 
frequency of coitus and ejaculation and concluded that taking into account other aspects of 
sexuality than ouly ED, a higher proportion of patients had complaints in this regard after 
ERT. The need of adequate information on sexuality prior to ERT treatment was emphasized 
(99). 
Retrospective studies published in the 90 's 
In this era of PSA-testing, ERT of PC was frequently characterized by more fields, 
shaped/customized blocks, a computer plarming system and 3D treatment plans 
(54,55,60,69,86,88). QoL became also important in ERT trials although most questionnaires 
were still primarily related to urinary and bowel treatment sequelae. An overview of the 
retrospective studies published in the 90's is given in Table 2. For the first time also partners 
were interviewed (85,86,88) and percentages of patients potent prior to ERT were reported in 
nearly all studies, except for a few (51,67,75,80). Post-radiation ED rates varied from 17 to 
84% (38,51,54,55,60,61,66,67,74,80,86-88,90,97) and, with regard to 3D-CRT, from 27% to 
49% (55,60,74,86). Different and sometimes conflicting results were reported regarding 
correlation of medical or surgical history and the occurrence of ED. Age correlated positively 
with ED in one study (61) but not in others (38,54,55,60); comorbidity, a history ofTURP or 
a RP correlated positively in two studies (51,86), but not in others (38,54,55,60,61,86,87). 
Tumor stage was not found to influence ED rates (38,51,54,55,60,61,86). Pre-ERT potent 
patients who received a dose of 75.6 Gy or more had an impotence percentage of 68% at 5 
years versus 52% for those treated to 70.2 Gy or less (54,55). Other studies could not 
corroborate these findings (38,60,86). Hormonal manipulation (54,55,87) was not correlated 
with ED, while patients marginally potent prior to radiation were more likely to become 
impotent following treatment (51,86). Volume of tissue irradiated did not influence sexual 
complications because the neurovascular bundles were always included in the full dose 
treatment field running along the edge of the prostate (67). 
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Helgason et al. were the first to link the decrease of sexual capacity to a change in QoL (87). 
The importance of time factor was stressed by some authors reporting an increase of ED 
occurrence with increasing follow-up (51,60). Nguyen et al. randomized 112 patients to 
conventional or 3D-CRT (70 and 78 Gy, respectively), reporting an overall ED rate of 49%, 
not different from the 47% and 52% for conventional and 3D-CRT techoiques, respectively 
(74). Special ERT beams such as proton, pion and neutron have also been reported to have a 
detrimental effect on potency (29,49,79) similar to those reported with the more common 
used photon beams. 
Prospective studies published in the 90's 
In the 90's a few studies were perfonned prospectively, reporting the number of patients 
potent prior to ERT and in most cases the exact follOW-Up time of ED evaluation (see Table 2 
for an overview). We think this is the only correct way to avoid recall bias of pretreatment 
potency status. These prospective studies revealed more realistic ED percentages, which 
appeared to be much lower than those reported in retrospective studies published in the same 
years. Although these prospective studies were carried out adequately, ED percentages still 
varied considerably, from 7 to 72% (47,65,69,70,85,98,109). Time factor, i.e. time since 
radiation, was again found to be very relevant (69,98). Tumor stage, radiation dose, 
comorbidity, TURP prior to ERT had no predictive value on sexual dysfunction after ERT; 
good proguostic factors were a lower age and pre-treatment functional erections (109). A 
trend that radiation field and size had a role in sexual function, i.e. the smaller the field size 
the better sexual functioning was found for the first time (69). 
Incidence of Erectile Dysfunction after Brachytherapy for Prostate Cancer Patients 
Results of radium BT in bladder and prostate cancer were reported as early as 1917 (116). 
Nowadays, much experience has been accumulated with various faIms of interstitial 
techoiques (retropubic, suprapubic, transperioeal), of prostate visnalization through 
ultrasound and computer tomography (CT) imaging, of treatment planning (pre and post-
implantation dosimetry) with the use of various isotopes such as 1-125, Iridium-l92 (Ir-192) 
and Pd-I03. BT was originally introduced (and gained popularity) to !intit the detrimental 
effects ofERT on bowel and urioary function but also with regard to sexual function. 
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Because of the vfTj :few papers specifically focussing on ED it is difficult to give a 
meaningful overview (see Table 3). In essence, the same problems as for ERT studies were 
encountered; there was often no clear definition of potency, most studies were of retrospective 
nature and did not report on comorbidity, with a few exceptions (24,30,32,39,43,44,50, 
52,53,72,106), and in most studies no percentages of patients potent prior to BT were given. 
Other complicating factors, whose specific effects on erectile function r.emam unclear, were 
the combination of BT and ERT and seeds implantation performed after lymph nodes 
dissection v.rith incision of the endopelvic fascia to mobilize the prostate gland. Percentages of 
ED after BT monotherapy were usually lower than after ERT alone. However, a selection bias 
might exist because patients who are highly motivated to maintain potency are more likely to 
choose BT. Furthermore, a lower average age, a better performance status and a more 
favorable tumor staging of patients undergoing BT, probably due to selection bias by the 
referring urologist and the radiation oncologist, could also explain the lower percentages of 
impotence rates after BT together with a rapid fall-off of isotopes that delivers the lowest 
radiation dose to the neurovascular bundles. 
In studies from the 70's ED ranged from 0 to 25% (14,20,23,24,82), being highest when BT 
was used in combination with ERT (20). Herr reported specifically on sexual potency 
following BT and stressed the importance of a thorough explanation to the patient of the 
procedure and its influence on sexual functioning. advocating the importance of sexual 
counseling (82). In the 80's percentages of ED following BT seemed to be higher than in the 
70's, ranging from 8 to 61%, probably because of the frequent combination with ERT 
(25,28,30-32,34,106). 
In the 90's, advances in radioisotope development, with the introduction of Pd-I03, 
sophisticated 3D computer-assisted dosimetry, intraoperative trans-rectal ultra sound (TRUS) 
availability, and introduction of the transperineal approach, produced a more homogeneous 
and reproducible implant than in the past with the retropubic route. In general, in studies 
using 1-125 andlor Pd-l03 the ED rates ranged from 2 to 51% (40,41,43-45,48,50,52,53,56-
59,68,89,95,96,105), with again the highest percentages found when BT and ERT were 
combined (41,45,78,95). 
The highest ED rates, ranging from 25 to 890/0, have been reported following the 
combination of a temporary Ir-192 implant followed by ERT (39,42,46,72). 
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With respect to the differences between 1-125 and Pd-I03, ED rates were 6-21% 
(40,43,44,56) and 15% (53), respectively. No statistically significant difference was found 
between 1-125 and Pd-I03 implants on ED (96), but in another paper Pd-I03 resulted in a 
worsening of sexual function (50). When the exact time of impotence evaluation was 
indicated in studies ofI-l25 or Pd-I03 without the combination ofERT, ED rates were at 12 
months 2-8% (48,50), at 24 months 6-21 % (40,50,89) and at 36 months 19% (44). One paper 
reported no differences in ED occurrence following BT alone or the combination ERT and BT 
(41). A new concept of "temporarily impotence" was introduced because of 
painfuVunconfortable erections after BT (43). For the first time an increase in erectile 
function was found in 21% of patients following BT (48) while a decrease in penile 
sensitivity suggested a neural component in the etiology of ED (96). 
Ejaculatory and other Sexual Dysfunctions 
The ability to achieve and sustain erections is ouly one component of the entire sexuality 
picture. Loss of libido and ejaculation disorders are very important as well. A deterioration of 
sexual activity has significantly been associated with the severity of ejaculatory dysfunction, 
mainly a decrease in volume or an absence of semen (117). Ejaculatory disturbances in BT 
studies varied from diminishing or absence of ejaculate volume (7%-45%) to discomfort 
during ejaculation (3-11 %) to hemospermia (5%) (24,32,40,43,68,82). 
Following ERT lack of ejaculation was reported in 2 to 56% (19,65,87,99). Dissatisfaction 
with sexual life was reported in 25-60% (83,109), a decreased libido in 8-53% (72,99,109) 
and a decreased sexual desire in 12-58% (40,66,72,87). One study reported a decreased 
intensity of orgasm, decreased frequency of erections and less erection rigidity, and decreased 
importance of sex (87). 
Comparative studies of Extemal Beam Radiotherapy versus Radical Prostatectomy 
Because of the growing popularity of modem 3D-CRT techniques in the 90's complications 
of ERT and RP were compared (for a summary of the studies see Table 4). Survival benefits 
of PC-treatments had to be balanced by acceptable side effects and ED was a bothersome 
complication of the surgical treatment approach. ED rates after RP seemed to be much higher 
than following ERT, therefore patients who wanted to preserve sexual potency were more 
frequently referred to the radiation department. 
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In comparative studies, ED rates after RP varied from 48 to 98% while after ERT these rates 
were 31-85% (2,62-64,71,76,81,91, 92,104), A meta-analysis including only men potent prior 
to treatment showed that the probability of maintaining normal erections after ERT was 0,69 
and after RP 0,42, difference statistically significant (118), A comment seems at place. The 
authors determined ED at one year post-treatment on the assumption that at this time the final 
effect of ERT is expected to be present and the recovery after surgery is expected to have 
been achieved. However, this interval might be too short to reveal all ERT effects; as 
previously reported there is a clear decrease in erectile function between 12 and 24 months 
following radiation (69,98). 
Concluding Remarks and Recommendations 
There are still no conclusive data on ERT techniques, field sizes, energy used and their 
specific influence on sexual function. Conventional and conformal techniques resulted in the 
same rates of ED. However, prospective studies with larger series, and the use of 
standardized validated instruments, have to confirm these findings. Conformal techniques 
using shaped blocks do not spare the neuro-vascular bundles because these are always entirely 
in the high-dose prostate field. No reliable data is at the moment available on the correlation 
between doses in this region and the occurrence of ED after ERT. Although the arteriogenic 
mechanism seems to be mainly involved this is certainly not the only one because radiation 
dose to the neurovascular region after BT has not been found different in potent and impotent 
patients. The radiation dose received by the corpora cavernosa, at the crura of the penis, might 
be also important in the etiology of ED but data are lacking. A multifactorial etiology has to 
be considered, taking into account comorbidity, previous TURP, drugs, and pre-treatment 
erectile function. Furthermore, not ouly a functional penis but a functional man, and also his 
partuer, has to be considered assessing sexual desire, satisfaction with sexual life, libido and 
frequency of intercourse as welL Prevention is a difficult matter: by accepting the hypothesis 
that radiation induces vascular damage, any methodology of decreasing the dose to the pelvic 
vascular structures would decrease ED rate. Thus with the modern Intensity Modulated Radio 
Therapy (IMRT) techniques, a higher percentage of PC patients might stay sexually potent 
after radiation. Much work has still to be done on the etiology of radiation-induced 
impotence. Time post-radiation therspy and ED evaluation has also to be considered. 
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It is not possible to draw final conclusions when evaluation is made at 6-12 months after ERT 
or BT, one should wait at least 18-24 months when ED occurrence has reached a maximum 
and remains stable further on. It is also obligatory to determine pre-treatment sexual 
functioning; high percentages (up to 60%) of patients may be impotent already before 
radiation therapy. A "standard" definition of (im)potence as advocated by the NIH should 
always be used and a standardized methodology of ED evaluation by using, prospectively, 
validated questionnaires on QoL and sexual functioning is mandatory. 
A better understanding of the etiology would allow a more specific knowledge of therspy 
possibilities. Improved penile blood flow through the cavemosal arteries induced by elective 
phosphodiesterase inhibitors can be effective when arteriogenic dysfunction is predominant. 
Sildenafil citrate (Viagra®) has been reported to be effective in up to 74% of patients 2 years 
or longer after ERT (119-121) and in 80% following BT (122), but in no case a randomized, 
placebo-controlled trial was performed. Also intracavernosal injection of prostaglandines or 
phentolamine-papaverine is effective (123), suggesting a predominant vascular etiology. 
Patients may also benefit of the implantation of a penile prosthesis (124). New drugs for ED 
are at the moment under evaluation such as the central agent apomorphine and a new class of 
phosphodiesterase inhibitors that might be more effective in post-radiation ED. Sildenafil 
taken at bedtime has been found to significantly increase noc1mnal erectile activity, especially 
in the older age group and in patients with vasculogenic ED (125). We could hypothesize t1tis 
might be a potential way of preventing or minimizing the vascular deterioration that usually 
occurs following radiation therapy. Finally, sexual counseling: patients need to be correctly 
infonned on the anatomy of the prostate, on the possible sequelae of radiation on their sexual 
life and functioning, including ejaculation disturbances, which are quite often neglected. They 
should also be informed about the various effective treatments for ED available nowadays: 
sildenafil, autoinjection therapy, vacuum pomp and erection prosthesis. 
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Table 1: Incidence of Erectile Dysfunction after Extemal Beam Radiotherapy (ERT) for Prostate Cancer: studies from the 70 ts and the 80 ts 
Author Year Patients Mean age* Patients potent Mean total dose Mean follow-up Incidence 
(reference) /I years (range) prior to ERT /I (%) Gy (range) months (range) % (1/) 
Studies from the 70ts 
Loh (12) 1971 36 66 (49-79) 19 (53) 70 (53-76) l1.a, (5-60) 84 (16/19) 
Rhamy (13) 1972 15 57 (39-73) n.a. n.a. up to 48 47 (7/15) 
Ray (15) 1973 310 63 (39-89) 96 (31) l1,a, (70-82) n.a 30 (29196) at 15 months 
Bagshaw (17) 1975 430 59 (n,a,) 110 (26) l1,a, (70-76) n.a. 41 (65/110) at 15 mOl1ths 
Mollenkamp (18) 1975 88 65 (47-84) n.a. n,a, (42-75) n,a, (12-60) 23 (20/88) 
McGowan (19) 1977 107 64 (50-79) n,a. l1,a, (45-60) n,a, (24-65) 6 (7/107) 
Perez (8) 1977 112 l1,a, (40-81) n.ll. l1,a, (40-70) n,a, (12-60) 13 (15/112) 
Taylor (22) 1977 278 n.a, 108 (39) n,a, (65-75) n.a. 22 (241108) 
Studies from the 80's 
Tomic (83) 1983 12 66 (55-73) 12(100) 64 (58-71) 22 (6-66) 25 (9/12) 
Forman (33) 1985 240 68 (52-86) 105 (44) 65 (l1,a,) 401 (12-108) 43 (45/105) 
Asbell (35) 1988 445 68 (n,a,) n.a. l1,a, (45-72) 841 (l1,a,) II-53 (l1,a,) 
Bagshaw (36) 1988 914 63 (35-86) 434 (47) 70 (n,a,) up to 180 14 (n,a,) at 15 months 
Banker (9) 1988 85 n.ll. 26 (30) n,a, (45-70) l1,a, (8-12) 73 (19126) 
van Heeringen (99) 1988 18 71 (60-82) 11(61) 65 (n,a,) 20 (4-45) 27(3/11) 
Shipley (37) 1988 121 68 (n,a,) 54 (45) l1.a, (65-68) n,a, (60-114) 37 (20154) at >36 months 
n,a, data not available 
* mean age for entire group 
t median 
Table 2: Incidence of Erectile Dysfimction after Extemal Beam Radiotherapy (ERT) for Prostate Cancer: studies from the 90's 
Author Year Patients Mean age • Patients potent Mean total dose Mean follow-up Incidence 
(reference) /I _ years (range) prior to ERT /I ('){,) Gy_(range) months (range) % (112 
Retrospective studies 
Mameghan (38) 1991 218 671 (45-87) 42 (19) n,a, (50-65) 55 (n,a,) 45 (19142) at 24 months 
Jon1er (61) 1994 98 741 (55-89) 68 (77) n,a, (66-70) 311 (14-60) 84 (57/68) 
Helgason (87) 1995 53 70 (53-80) 33 (66) 63 (56-66) Ita, (18-24) 50 (26/53) 
Roach (88) 1996 124 721 (48-87) 60 (48) n,a, (59-87) 21 1 (7-40) 38 (23/60) 
Crook (97) 1996 192 70 (49-87) 158 (82) n,a, (60-66) 33 (12-72) 35 (55/158) 
Caffo (66) 1996 90 711(49-83) 45 (50) n,a, (60-70) 351 (6-86) 67 (30/45) 
Frallsson (67) 1996 199 711 (51-86) n.a. 65 (61-69) 48 (24-56) 56 (n,a,) 
Mantz (51) 1997 114 68 (52-85) n.a. n,a, (65-70) 18 (n,a,) 2 (n,a,) at I month 
8 (n,a,) at 12 months 
25 (n,a,) at 24 months 
34 (lI,a,) at 36 months 
Fossa (90) 1997 114 69 (n,a,) 22 (19) n,a, (64-66) n.a. 61 (13/22) 
Nguyen (74) 1998 101 l1.a. 81 (80) lI,a, (70-78) >24 49 (40/81) 
Zelefsky (54) 1998 743 691 (51-84) 385 (52) n,a, (65-81) 361 (12-92) 27 (104/385) 
Zelefsky (55) 1999 743 691 (51-84) 544 (73) lI,a, (65-81) 421 (18-109) 39 (21l1544) 
Fransson (75) 1999 83 73 (55-85) n.a. 65 (lI,a,) 96 (72-104) 65 (54/83) at 96 mOllths 
Johnstolle (80) 2000 46 80! (62-90) n.a. 67 (63-70) 1671 (120-276) 76 (35/46) 
Wilder (60) 2000 51 681 (n,a,) 35 (69) 74 (66-79) 151 (n,a,) o at 12 months 
17 (9/51) at 24 mOllths 
37 (19/51) at 36 mOllths 
Table 2: continued 
Author 
(reference) 
Y car Patients Mean age ~ Paticnts potent Mean total dose :Mean follow-up 
1/ years (range)jlrior to ERT 11 (%) Gy (r<ltlge) months (range) 
Prospective studies 
Zinreieh (85) 1990 27 68 (52-80) 10 (37) n,a, n,a, 
Pilepieh (47) 1995 230 71 1 (49-84) 102(44) n.a. (65-70) 541 (n.a.) 
Beekendorf (I 09) 1996 67 68 (54-84) 40 (60) 68 (58-70) n.a. (8-12) 
Beard (69) 1997 121 n,a, 69 (57) n.a (65-72) n.a. 
Borghede (70) 1997 184 67 (46-83) 134 (73) 701 (60-72) 46 (24-96) 
Tumer (98) 1999 290 69 (44-82) 182 (63) 661 (60-70) 231 (n.a.) 
n,a, data not available 
• mean age for entire group 
t median 
tat survey 
Incidcnce 
% (1/) 
20 (2110) at 12 months 
72 (741102) 
33 (13140) 
57 (39169) at 3 months 
64 (44169) at 12 months 
7 (91134) 
38 (561146) at 12 months 
59 (40168) at 36 months 
Table 3: Incidence of Erectile Dysfunction after Brachyterapy (BT) for Prostate Cancer 
Author 
. 
Year Isotope/Technique ERT Patients Mean age Patients potent Prescribed dose BTTotal dose ERTMean follow-up Incidence 
(reference) 1/ years (range) prior to BT 1/ (%; Gy (range) Gy (range) months (range) % (1/) 
Whitmore (14) 1972 1-125/RTP 26 11.a. 15 (58) n,a, (80-160) n,a, (3-24) 13 (21l5) 
Carlton (20) 1976 Au-198fRTP ERT 109 n.a n.a. n,a, (25-35) n,a, (40-50) n,a, (12-120) 25 (23/109) 
Hilaris (23) 1976 I-I 25fRTP 1I2 58 (36-77) n.a. n.a. 42 (24-72) 0 
Fowler (24) 1979 1-125fRTP 116 60 (36-77) 109 (94) l1.a. 23 (1-90) 7 (8/109) at 15montb 
Herr (82) 1979 1-125fRTP 51 65 (52-74) 41 (80) n.a. >6 2 (!f41) at 6 months 
Shipley (25) 1980 1-125/RTP ERT 30 641 (52-76) 19 (63) 160 10 >12 II (2/19) 
Ross (28) 1982 H25fRTP ERT 57 65 (51-75) n.a. 100 40 22 (I-52) 50 (29/57) 
Flanigan (30) 1983 1-125fRTP ERT 25 61 (51-70) 23 (88) l1.a. 10 30 (12-48) 26 (6/23) 
Schellhammer (31) 1983 I-I 25fRTP 90 62 (46-77) l1.a. 160 >12 8 (n,a,) at 12 months 
25 (n,a,) at 36 month, 
Kwong (32) 19S4 1-125/RTP 65 63 (45-78) 45 (69) 160-180 11.a. 13 (6/45) 
Bosch (34) 1986 Ir-I92/TPR ERT 43 64 (53-73) 31 (73) 30 40 n.a. 61 (19f3l) 
DeLaney (106) 1986 I-I 25fRTP ERT 64 64 (48-79) 34 (53) 160 10 60 (24-108) 29 (10/34) 
Syed (39) 1992 Ir-I92/TPR ERT 200 65 (49-81) 100 (50) 30-35 30-40 n.a. 25 (n,a,) 
Arterbery (40) 1993 H25/TPR 21 67 (59-7S) 18 (86) 160 13 (2-24) 6 (!fIS) at 24 monUlS 
Blasko (41) 1993 1-125; Pd-103/TPR ERT 469 n,a n.a. 160-ll5! 45 38 (12-78) <70 15;>7050 
Stromberg (42) 1993 Ir-192/TPR ERT 57 63 (40-77) 46 (80) 30-35 36 721 (0-102) 57 (26/46) at 24 month 
Kleinberg (43) 1994 I-I 25/TPR 31 671 (58-SO) 18 (58) 140-160 >12 6 (Ill 8) 
Wallner (44) 1994 I-I 25/TPR 62 671 (58-80) 38 (61) 160 191 (6-55) 19 (7/38) at 36 months 
Kaye (45) 1995 1-125/TPR ERT 72 71 (50-83) 44 (61) 120-160 45 26 (ll-60) 25 (1!f44) at 12 month, 
Maliinez (46) 1995 Ir-I92/TPR ERT 59 n.a 11.a. 15-19 46 19(4-36) 38 (n,a,) 
Table 3: continued 
Author Year Isotope/Technique ERr Patients Mean age 
, 
Patients potent Prescribed dose BT Total dose ERTMean follow-up 
(reference) II years (range) prior to BT II (%; 
Stone (48) 1995 1-125; Pd-I03/TPR 58 68 (49-75) 12 (21) 
Chaikin (96) 1996 1-125; Pd-I03/TPR 37 n.a. 27 (73) 
Stock (89) 1996 1-125; Pd-I03rrPR 97 69t (49-82) 64 (66) 
Stock (50) 1996 1-125; Pd-I03/TPR 89 69t (49-82) 65 (73) 
Arterbery (68) 19971-125; Pd-l03/TPR 51 n.a. 35 (69) 
Koutrouvelis (52) 1998 1-125; Pd-l03/n.a. 130 71t (49-90) n.a. 
Joly (72) 1998 Jr-I92/TPR ERT 71 68 (51-82) n.a. 
Sharkey (53) 1998 Pd-l03/TPR 434 73 (52-83) n.a. 
Zelefsky (56) 1999 1-125rrPR 145 64t (n.a.) 128 (88) 
Kestin (57) 2000 Ir-192/TPR ERT 161 69t (n.a.) n.a. 
Sanchez-Ortiz (105) 2000 1-125; Pd-l03/TPR ll4 69 (n.a.) 81 (71) 
Sharkey (58) 2000 Pd-l03/TPR 299 73 (48-88) n.a. 
Ze1efsky (59) 2000 1-125/TPR 248 65t (45-80) 221 (89) 
Isotope: Gold-l98 (Au-198); Iridium-192 (lr-I92); lodine-125 (1-125); Palladium-I 03 (Pd-I 03) 
Technique: Retropubical (RTP); Transperineal (TPR) 
Combination with extemal beam radiotherapy (ERT) 
n.a. data not available 
• mean age for entire group 
t median 
11-125IPd-103 respc(;lively 
Gy (range) Gy Jrange) months (range) 
n.a. 12 (6-24) 
n.a. 18 (5-32) 
160-ll51 18t (6-51) 
160-ll51 1St (I-52) 
n.a. n.a. 
160-1201 n.a. (6-24) 
15 40-45 n.a. 
n.a. 28 (12-60) 
140-160 241 (6-103) 
6.-10 46 34t (5-86) 
ll5 23(4-72) 
n.a. n.a. 
140-160 481 (12-126) 
Incidence 
% (II) 
8 (1112) at 12 month 
45 (12/27) 
21 (13/64) at 24 mont 
2 (2/64) at 12 month 
6 (4/65) at 24 month, 
13 (4/35) at 6 month 
5 (n.a.) 
89 (n.a.) 
15 (n.a.) 
21 (28/132) 
29 (47/161) 
51 (41181) 
15 (n.a.) 
29 (64/221) 
Table 4: Incidence of Erectile Dysfunction in studies ofRadieal Prostatectomy (RP) versus Extemal Beam Radiotherapy (ERT) for Prostate Cancer 
Author Year RP patients ERT patients Mean age· RP Nfean age t ERr Patients potent Patients potent NSINNSRP 
(reference) n 11 years (range) years (ra:nge) prior to RP II (%) prior to ERT II (%) 
Lim (64) 1995 89 46 65 (41-78) 71 (62-85) 73 (82) l1.a. NSINNS 
Litwin (62,63) 1995 98 56 70 (n.a.) 76 (n.a.) n.a. l1.a. NSINNS 
Helgason (91) 1997 22 37 69 (54-79) 69 (55-78) n.a. n.a. Ita. 
Shrader-Bogen (71) 1997 132 142 66 (n.a.) 75 (n.a.) n.a. n.a. 11.a. 
Y.arbro (104) 1998 68 53 69 (n.a.) 75 (n.a.) n.a. n.a. n.a. 
Taleot! (92) 1998 125 135 61 (41-72) 68 (49-86) n.a. (68) n.a. (55) NSINNS 
McCammon (2) 1999 203 257 63 (43-74) 70 (n.a.) n.a. H.a. NSINNS 
Lilleby (76) 1999 108 154 63 (47-78) 66 (48-81) B.a. n.a. NSINNS 
Smith (81) 2000 1247 189 681 (n.a.) 741 (n.a.) <70 (81); >70 (55) <70 (61); > 70 (50) n.a. 
NS:=:nerve-sparing RP; NNS=non-nerve sparing RP 
n.a. data not available 
• mean age for entire group 
t median 
t at survey 
Table 4: continued 
Mean total dose Mean follow-up RP Mean follow-up ERT 
Gy (range} m(mthsJrallge) -,nonths (range) 
n.a. (65-72) n.a. (3-18) n.a. (3-18) 
66 (n.a.) n.a. (60-72) n.a. (60-72) 
63 (n.a.) l1.a. (18-24) l1.a. (18-24) 
n.a. 32 (12-60) 41 (12-60) 
n.a. 30 (n.a.) 25 (n.a.) 
n.a. n.a. n.a. 
n.a. 401 (12-144) 311 (12-121) 
l1.a. (64-66) 41 (12-116) 31 (12-121) 
B.a. 34 (l1.a.) 33 (l1.a.) 
Incidence RP 
% (1/) 
97 (71173) 
71 (n.a.) 
86 (n.a.) 
83 (110/132) 
98 (n.a.) 
95 (n.a.) at 3 mOl1ths 
91 (n.a.) at 12 mOl1ths 
67 (132/198) 
Incidence ERT 
% (1/) 
54 (25/46) 
64 (l1.a.) 
57 (n.a.) 
70 (99/142) 
65 (l1.a.) 
48 (n.a.) at 3 mOl1ths 
61 (l1.a.) at 12 months 
60 (1471246) 
48 (52/108) at 12 mOl1ths 31 (45/154) at 12111011ths 
<7075; >70 94 <7071; >70 85 
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Summary and Conclusions 
The use of visual sexual stimulation (VSS) in the differential diagnosis of men with erectile 
dysfunction (ED) has been suggested by different authors and strongly advocated by our 
group (see Appendix). The combination of VSS with penile vibration (VIE) using a small 
vibrator, attached to an erectiometer and applied to the frenulum area of the glans penis, 
proved to be an excellent method in determining (remaining) erectile capacity in ED-patients. 
Following priming with VSS and VSS plus VIE, a low dose intracavemosal injection (lCI) of 
a vasoactive drug was in the vast majority of patients effective in eliciting an erection 
sufficiently rigid for sexual intercourse. To the patient and the doctor such a penile response 
means that the neurovascular mechanism is intact and that the male is potentially sexually 
potent. However, in cases of no penile response, this has no significant diagnostic meaning. 
Various reasons can be responsible for the absence of penile response, i.e. somatic or 
psychological, e.g. psychic inhibition, or the video may not be sexually arousing. 
\\Then using this psychophysiological screening method on a routine basis in 406 
consecutive patients with various ED etiologies it appeared that up to 80% of the patients 
responded with a good erection (Chapter 2). Although men under 40 years of age responded 
significantly better than men over 40, no difference in penile response was fOlUld between 
ages 40 and 80. This demonstrates that this methodology also has its significance in testing 
older men with sexual dysfunction. Also the addition of VIE and ICI increased penile 
response in virtually all patients of all ages. In summary, VSS alone caused a penile response 
in one third of the patients, the combination of VSS and VIE caused 52% of the patients to 
respond, while VSS with ICI elicited a good penile response in 82% of the patients. 
Nowadays we would advise to use this psychophysiological diagnostic screening (PDS) only 
in those ED-patients where medical history reveals no erection whatsoever: not during the 
night, not in the morning, not with sexual activities, either with the partner or solo with 
masturbation. PDS remains a very useful instrument for research purposes since it nicely 
shows the erectile capacity of a patient. 
In the same group of 406 patients a follow-up investigation was carried out in o"der to 
ascertain current sexual functioning 1 to 4 years after the consultation at the 
psychophysiological laboratory (Chapter 3). An extensive questionnaire was developed and 
mailed to all patients; a representative sample of237 (54%) patients responded. 
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About half of the patients reported to have undergone some form of ED treatment 
(autoinjection treatment, vacuum device, sex therapy/counseling). It is important to note that 
this study was carried out before sildenafil (Viagra®) had become available. More than half 
of the patients reported no change in their original complaint, about a quarter had improved 
and another quarter reported a further deterioration of their sexual dysfunctioning. No 
statistically significant correlation was found between original psychophysiological 
responding and current satisfaction scores. Only the occurrence of daytime spontaneous 
erections and the frequency of morning/night erections (information easily obtained through 
history taking) correlated positively with present satisfaction with sexual functioning. Overall. 
these results are somewhat disappointing because they clearly show the need for a more 
appropriate therapeutic approach to patients with erectile difficulties. Furthermore, we believe 
that the results of this follow-up study clearly indicate that effective somatic treatments such 
as autoinjection therapy, vacuum device therapy or drug medication (even sildenafil 
treatment) should be combined with sexual counseling or sex therapy in order to further 
improve their efficacy. 
Surgical castration, trauma or agenesis of a testicle may produce psychosexual problems, 
especially in young men. Testicular prostheses (TP's) are easy to iusert, complications are 
mild and cosmetic results are quite satisfactory. We retrospectively studied 30 patients (mean 
age 30 years) who had received a TP earlier in their life (Chapter 4). About 40% of the men 
considered their body appearance greatly improved and 27% slightly improved after receiving 
a TP. About 60% of the patients were satisfied with their current sexual life, 10% complained 
of ED and 45% were bothered by premature ejaculation. The relatively low frequency of 
sexual problems may be related to the positive body image and the high satisfaction rate after 
the insertion of a TP. Men of all ages and their partners benefited from the restoration of a 
normal social and sexual functioning. 
Peyronie's disease (PD) is a mysterious condition; a genetic predisposition for a fibrotic 
response most likely leads to rupture of microvasculature foHowed by fibrosis in the penis in 
these subjects. This results in a plaque of scar tissue in the tunica albuginea of the penis and 
consequently in penile curvature, usually with discomfort during sexual activity. Many 
treatment options have been advocated, all more or less with positive study outcomes: vitamin 
E, Potaba, colchicine, tamoxifen or intralesional injections with corticosteroids or Verapamil. 
PD is self-limiting in 50% of the patients within 12-18 months. However, if penile discomfort 
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is long lasting therapy is indicated. In cases of severe penile curvature surgery remains the 
therapy of first choice. We investigated through questionnaires 179 patients who had received 
external beam radiotherapy (ERT). This proved to have been effective in a decrease of penile 
pain in 83% of the patients and of penile curvature in 23%, mostly within 3 months. No side 
effects were observed (Chapter 5). 
Sexual functioning in patients following ERT for PD is a much neglected area We 
evaluated 106 patients (mean age 69 years) who had received ERT a mean of9 years earlier, 
by analyzing the answers to an extensive questionnaire regarding sexual desire, significance 
of sex, frequency and rigidity of spontaneous erections (=morning/night erections), difficulty 
in getting and maintaining an erection (Chapter 6). About one third of the patients never had 
spontaneous erections, about halfhad sometimes or always difficulty in getting an erection. A 
decrease had occurred in sexual interest, in sexual activity and in sexual pleasure after ERT 
for PD in 28%, 67% and 49%, respectively, but patients were also 9 years older. About half of 
the patients reported not being satisfied with their current sexual life. All these variables were 
correlated with age. Thus, complaints in sexual functioning following ERT for PD were age-
related. Therefore, sexual counseling before and after ERT is highly recommended, since we 
found that after ERT for PD erectile function improved ouly in 13% of patients. 
Prostate cancer (PC) has become the most frequent malignancy in men in Western 
countries. Standard treatments comprise radical prostatectomy (RP), ERT or brachytherapy 
(BT) with or without hormonal therapy, or observation. Choice of treatment is often 
determined by tumor staging, patient's age and comorbidity, urologist's and patient's 
preferences. The impact on sexual activity and sexual functioning of PC diagnosis and 
subsequent therapy is quite frequently ignored. Receiving the diagnosis of PC causes a 
significant decrease in sexual activity, interest and pleasure. We studied 158 PC-patients 
awaiting treatment (RP or ERT) (Chapter 7). An increase in problems with getting an 
erection has been observed in up to 20% of the patients. A significant decrease of patients 
who are sexually active after receiving the diagnosis compared to 4-9 weeks previously has 
also been observed. Patients awaiting RP were significantly younger with a lower incidence 
of cardiovascular diseases than patients awaiting ERT. The RP-group was significantly 
sexually more active and reported significantly fewer problems in getting or maintaining an 
erection than patients in the ERT-group. Age was the most relevant variable responsible for 
the differences encountered in sexual functioning between RP- and ERT -patients. 
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This can easily be explained by a physician's bias: i.e. the doctor's preference for surgical 
treatment in younger men. Baseline data on sexual functioning prior to treatment are relevant 
for later comparisons with data after treatment and to detect treatment related morbidity. 
Reviewing the literature on sexual (dys)function following radiotherapy (ERT andlor BT) 
for PC appeared cumbersome and not without caveats (Chapter 8). There are many studies 
published on this subject but conclusive data are still lacking on the influence of techniques, 
e.g. field sizes and energy on sexual functioning. Methodological problems encountered were 
manifold: which questionnaire was used? Was it validated? Was it dealing only with erections 
or did it offer a more comprehensive picture of patient's sexuality: his desire, ejaculation, 
satisfaction with sexual life, frequency of erections and of intercourse? In very few studies 
extensive, validated questionnaires were used. Furthermore, the definition of 
potency/impotence was quite variable. We strongly recommend the use of a standardized 
definition. for instance the one proposed by the Natioual Institute of Health and somewhat 
adapted: impotence is the consistent (or prevailing) inability to attain and maintain a penile 
erection sufficient to permit satisfactory sexual activity, i.e. intercourse or masturbation. ED 
is. of course, more than only a non-functional penis, other sexual parameters of the ED-
patient such as libido, interest in sex and satisfaction with sexual life should also be taken into 
account. Therefore, a simple unequivocal definition of potency/impotence is needed. For 
study purposes a more complex evaluation of patients' erectile function should be carried out; 
if a patient defines his own erection as sufficient for sexual intercourse or masturbation he 
should be considered potent. With these shortcomings it is difficult to summarize from the 
literature the incidence of ED after ERT for PC. This varies in fact from 6 to 84% in studies 
published in the 70's, from 11 to 43% in studies of the 80's, from 0 to 84% in retrospective 
studies of the 90's and presumably more reliably from 7 to 64% in prospective studies of the 
90's. After BT these percentages range from 25 to 89% with the combination of ERT and 
from 2 to 51 % using Iodine-l25 or Palladium-103 seeds. Conformal and conventioual 
techniques do not seem to differ much in the occurrence of ED , 52% versus 47% respectively. 
A much neglected parameter in many studies is the time of ED evaluation following 
treatment. There is a clear increase in the occurrence of ED with increasing follow-up time. 
Therefore, it is obligatory to wait at least 18-24 months before final conclusions can be 
drawn. The common belief that the incidence of ED after radiation is lower than after RP has 
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to be changed. If one waits long enough the ED-percentages following ERT and BT will 
reach similar values as after RP. 
The etiology of ED after radiation for PC is not completely understood. The most likely 
cause is a damage of the neurovascular bundles by the radiation. A better understanding of the 
etiology would certainly allow more therapeutic options. Sildena:fil citrate (Viagra®) has been 
reported to be effective in up to 74% of patients two years or more after ERT and 80% after 
BT (no follow-up time indicated). These results cannot be considered conclusive because in 
no case a randomized, placebo-controlled, double-blind trial has been performed. In an 
ongoing study (randomized, placebo-controlled, double-blind) in 60 patients, performed in the 
Department of Radiation Therapy of the University Hospital Rotterdam-Daniel den Hoed 
Cancer Center, our first results indicate that 100 mg sildenafil citrate is effective in 50% of 
our patients. In this study patients using nitrates for cardiovascular comorbidity were 
excluded. For those patients autoinjection therapy or penile prosthesis still remain a good 
alternative in the treatment of radiation-induced ED. 
In summary, we believe that patients awaiting treatment for PC should be correctly 
informed about the possible sequelae of radiation on their sexual life and sexual functioning, 
including ejaculatory disturbances. Patients should also be informed about the various 
effective and available treatments for ED, should such a condition occur following PC-
treatment. 
Finally: sex: does it matter in cancer patients? The answer comes from a 71 years old 
patient after 4 years of unsatisfactory sexual activity following ERT for his prostate 
carcinoma, using sildenafil (Viagra®): "At 7 am. I took the "pill", at 8.15 a.m. I started with 
foreplay, with quite reasonable results. At penetration I mew right away .. .it is going to be as 
in the old days; after a few minutes I did get a good erection and it felt as in the pastl A 
fantastic experience!" (letter of a patient). 
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Samenvaffing 
Visuele seksuele stimulatie (VSS) gecombineerd met vibrotactiele stimulatie van de penis 
(VIE), met een kleine vibrator in het frenulum gebied van de penis, is een excellente methode 
in de differentiaal diagnose van mannen met erectiele disfunctie (ED) om de (nog) aanwezige 
potentie te bepalen (zie Appendix). Na voorbereidende stimulatie met VSS en VSS+VIB is 
een intracavemeuse injectie OCI) met een lage dosis van een vaso-actiefmiddeI (bijvoorbeeld 
prostaglandine of de combinatie papaverine/fentolamine) vrijwel altijd voldoende voor het 
veroorzaken van een (vrijwel) volledige erectie, stijf genoeg voor seksuele activiteit. Deze 
penisrespons Iaat dus zien dat het neurovasculaire mechanisme intact is en dat de man in 
principe seksueel potent is. Indien er geen respons optreedt hoeft dit geen diagnostische 
waarde te hebben. Meerdere oorzaken zouden dit "falen" kunnen verklaren, somatisch 
(gebruik van bepaalde medicijnen; vasculaire insufficientie), maar ook psychologisch 
(bijvoorbeeld een psychische inhibitie, of de video is seksueel met opwindend voor de man op 
dit moment). 
We hebben routinematig VSS, VSS+VIB and ICI gebruikt bij 406 opeenvolgende patienten 
van verschillende ED etiologie; 80% van de patienten reageerde met een goede erectie 
(Hoofdstuk 2). Mannen onder de 40 jaar gaven een betere respons dan mannen boven de 40, 
maar er werden geen verschillen gevonden tussen de leeftijdsgroepen 40-60 en 60-80 jaar. 
VSS alleen gaf een goede penisrespons in eenderde van de patienten, de combinatie van VSS 
en VIE bracht de respollS tot 52% en VSS+ICI tot 82%. Momenteel adviseren wij deze 
diagnostische methode bij patienten met ED indien anamnestisch gem erecties meer worden 
gerapporteerd, niet 's nachts, niet bij het wakker worden en niet tijdens seksuele activiteit 
(met partner ofbij solo-masturbatie). 
In diezelfde groep van 406 mannen werd een follow-up onderzoek uitgevoerd om het 
seksueel functioneren te bepalen 1-4 jaar na de eerste onderzoeken in het psychofYsiologische 
laboratorium (Hoofdstuk 3). Van de 237 mannen (54%, representatiefvoor de gehele groep) 
die reageerden, gebruikte (of had gebruikt) ongeveer de helft enige behandeling v~~r ED 
(autoinjectie therapie, vacuUm pomp, seksuele counseling). Tijdens deze studie was sildenafil 
citraat (Viagra®) nog niet op de marlct. Meer dan de helft van de patienten rapporteerde geen 
verschil ten opzichte van de oorspronkelijke klachten, een kwart was verbeterd en een kwart 
was seksueel slechter gaan functioneren. 
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Er werd geen significant verschil gevonden tussen de oorspronkelijke respons in het 
laboratorium en de huidige tevredenheid scores; alleen spontane erecties en het hebben van 
erecties bij het wakker worden of's nachts, correleerde positief met het huidige seksueel 
functioneren. Deze resultaten zijn enigszins teleurstellend want zij tonen aan dat de 
somatische therapie bij mannen met ED (zoals autoinjectie therapie, vacuiim pompen en ook 
tegenwoordig sildenafil) in veel gevallen toch niet voldoende is. Ons advies is dat de 
somatische therapie gecombineerd wordt met begeleiding, of met seksuologische counseling. 
Chirurgische castratie, een trauma of agenesie van een testikel kan psychoseksuele 
problemen veroorzaken, voora! bij jonge mannen. Testis prothesen zijn eenvoudig te 
implanteren, complicaties zijn gering en de cosmetische resultaten zijn zeer redelijk. In 
Hoofdstuk 4 hebben wij gerapporteerd over een onderzoek bij 30 mannen (gemiddelde 
leeftijd 30 jaar) die eerder een prothese hebben gekregen. Ongeveer 40% van deze mannen 
vond hun "body image" sterk. en 27% licht verbeterd na de implantatie. Zestig procent was 
teVTeden met hun huidige seksuele leven, 10% klaagde over ED en 45% over vroegtijdige 
zaadlozing. Het lage percentage van seksuele problemen kan gerelateerd worden aan een 
positieve "body image" en een hoge tevredenheid na implantatie van een testis prothese. 
De ziek-te van Peyronie is een mysterieuze aandoening met een onduidelijke oorzaak. Een 
trauma van de penis in erectie veroorza.a.k.-t mogelijk schade aan de microvasculatuur met als 
gevolg fibrosis van de penis bij mannen met predispositie voor zulk een fibrotische respons. 
Het gevolg is een plaque van littekenweefsel in de tunica albuginea met als gevolg een 
kronnning van de penis in erectie en pijnkJachten, meestal tijdens seksuele activiteit. In de 
loop van de jaren zijn er verschillende behandehnethodes geprobeerd, met uiteen10pende 
resultaten, bijvoorbeeld: vitamine E, Potaba, colchicine, tamoxifen, en verder corticosterolden 
of Verapamil toegediend locaal in de plaque. De ziekte van Peyronie is "self-limiting" bij 
50% van de mannen, binnen 12-18 maanden. Bij een forse verkromming is cbirurgie de eerste 
behandeloptie, doch ook radiotherapie is een geaccepteerde behandeJing. We analyseerden het 
effect van uitwendige radiotherapie in 179 patienten (Hoofdstuk 5). 83% rapporteerde een 
vermindering van de pijn en 23% had een vermindering van de verkromming, meestal binnen 
3 maanden en zonder bijwerkingen. 
Het seksueel functioneren van patienten met de ziekte van Peyronie krijgt in de 
internationale literatuur weinig aandacht. Wij evalueerden 106 patienten (gemidde1de leeftijd 
59 jaar), die gemiddeld 9 jaar eerder bestraald waren, met een uitgebreide vragen1ijst over hnn 
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huidige seksueel functioneren: zin in seks, seksuele verlangens, frequentie en rigiditeit van 
erecties en eventuele problemen met het krijgen en behouden van een erectie (Hoofdstuk 6). 
Ongeveer eenderde van de mannen ervaarde noeit spentane (=ochtend/nacht) erecties, de helft 
had soms of altijd problemen bij het krijgen van een erectie. Een vermindering in seksuele 
interesse, seksuele activiteit en seksueel plezier na radiotherapie in vergelijIcing met v66r 
behandeling werd gerapporteerd in respectievelijk 28%, 67% en 49%. Het is belangrijk te 
bedenken dat de patienten ook gemiddeld 9 jaar ouder waren geworden. Ongeveer de helft 
van de patienten was ontevreden over hun huidige seksuele leven. Deze variabelen waren 
gecorreleerd met leeftijd. Op grand van deze resultaten bevelen wij seksuele counseling sterk 
am, zowel v66r als na radiotherapie voor de ziekte van Peyronie, aangezien de erectiele 
functie bij slechts 13% van de patienten verbeterde. 
Prostaatkanker wordt behandeld met een radicale prostatectomie, uitwendige of inwendige 
radiotherapie (brachytherapie), met of zonder hormonale therapie, of observatie (=geen 
behandeling). De therapiekeuze wordt vooral bepaald door tumorstadium, de leeftijd en co-
morbiditeit van de patient, en de voorkeur van de uroloog en de patient. De invloed van de 
diagnose ''prostaatkanker'' en van de daarbijbehorende therapie op de seksuele activiteit en 
het seksueel functioneren van de patient wordt regelmatig onderschat of vergeten. AIleen al 
de diagnose "'prostaatkanker" veroorzaakt frequent een vermindering van seksuele activiteit, 
interesse en plezier. Bij 20% van de patienten wordt een toename gevonden van problemen 
bij het krijgen van een erectie en tevens is er een vermindering in seksuele activiteit 
vergeleken met 4-9 weken voorafgaande aan de diagnose (Hoofdstnk 7). Onderzocht werden 
158 patienten die prostaatkanker hadden en in afWachting waren van behandeling, Of een 
prostatectomie, of radiotherapie. Patienten die een prostatectomie zouden ondergaan waren 
meestal jonger en hadden minder vaal< een cardiovasculaire voorgeschiedenis dan patienten 
die bestraald zouden gaan worden. Voorts waren de patienten in de chirurgiegroep vaker 
seksueel aetief en hadden ze minder frequent ereetiestoonllssen dan patienten in de 
radiotherapiegroep. Leeftijd was de meest relevante variabele bij het verklaren van alle 
versehillen tussen de twee groepen. Deze versehillen in seksueel funetioneren zijn dus in 
belangrijke mate te verklaren door de therapiekeuze van de dokter: jongere mannen wordt 
vaker een operatie voorgesteld. Data over het seksueel functioneren voorafgaande am de 
behande1ing zijn belangrijk om later te kunnen vergelijken met data na de behandeling en 
voor de evaluatie van de latere morbiditeit van de behandeling. 
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Het laatste Hoofdstuk (8) in dit proefscbrift is een literatuuroverzicht over seksuele 
(dis)functie na radiotherapie voor prostaatkanker. Er zijn geen definitieve gegevens over de 
invloed van de radiotherapeutische techniek, zoals veldgrootte en energie, op het seksueel 
functioneren. In de literatuurstudie bleken er veelvuJdig methodologische onduidelijkheden: 
welke vragenlijst werd gebruikt? was deze gevalideerd? werd er alleen vragen over erecties 
gesteld? of oak over andere aspecten van het seksuele leven van de patient: interesse in seks, 
tevredenheid met seksuele Ieven, frequentie van erecties en van coitus? Slechts in een klein 
aantal studies werden gevalideerde vragenlijsten gebruikt. Ook de definitie van 
potentieiimpotentie was heel verschillend. Naar ons idee zou een gestandaardiseerde definitie 
gebruilct moeten worden, bijvoorbeeld die van de 'National Institute of Health', met enige 
aanpassingen: impotentie (=ED) is het constante (of overwegend) onvermogen om een erectie 
te lcrijgen en te behouden die voldoende is voor seksuele activiteit (coItus of masturbatie). 
Maar ED is meer dan alleen een niet-functionele penis, ook andere seksuele aspecten zijn van 
belang zoals libido, interesse in seks en tevredenheid met het seksuele leven. Voor 
fysiologisch laboratoriumonderzoek kan een complete evaluatie van de erectiele functie nodig 
zijn, maar als de patient zelf zijn erecties de:£inieert als voldoende voor seksuele gemeenschap 
of masturbatie dient hij als potent beschouwd te worden. Gezien de eerdere genoernde 
moeilijkheden bleek het lastig om uit de literatuur tot een betrouwbare schatting te komen van 
de incidentie van ED na radiotherapie v~~r het prostaatcarcinoom. Percentages varieren 
tussen 6 en 84% in studies uit de jaren 70, van 11 tot 43% in studies uit de jaren 80, van ° tot 
74% in retrospectieve studies uit de jaren 90 en -waarschijnlijk reeJer- percentages van 7 tot 
64% in prospectieve studies uit de jaren 90. Na de brachytherapie zijn de ED-percentages 25 
tot 89% in combinatie met uitwendige bestraling en 2 tot 51 % met het gebruik van 1-125 of 
Pd-I03 zaadjes. Confonnatie en conventionele radiotherapie lijken niet verschillend te zijn in 
het percentage van ED na behandeling: 52% en 47% respectievelijk. 
Een ander belangrijk aspect was de tijdsperiode na behandeling warmeer ED werd 
geevalueerd. Er werd een duidelijke toename waargenomen van ED bij een langere follow-up. 
Daarom is het noodzakelijk om minstens 18-24 maanden te wachten voordat betrouwbare 
conc1usies getrokken kunnen worden. Een en ander betekent dat het idee dat de mcidentie van 
ED na radiotherapie lager is dan na prostatectomie, niet langer meer opgaat. Immers, indien 
men lang genoeg wacht worden de percentages van ED na uitwendige en inwendige 
radiotherapie vergelijkbaar met die na (zenuwsparende) radicale prostatectornie. 
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De etiologie van ED na radiotherapie is nog onduidelijk. De meest waarscbijnlijke oorzaak is 
schade aan de neurovasculaire bundels door de dosis van de radiotherapie. Meer duidelijkheid 
over de oorzaak zou meer therapeutische opties bieden. Sildenafil citraat (Viagra®) is 
effectief gebleken in 74% van de patifuten na uitwendige radiotherapie (2 jaar of langer) en 
80% na brachytherapie (tijd niet vermeld). Maar deze resultaten komen uit studies die niet 
gerandomiseerd, niet placebo-gecontroleerd en niet dubbel-blind zijn. Wij hebben een 
onderzoek verricht bij 60 mannen (weI gerandomiseerd, placebo-gecontroleerd en dubbel-
blind) en de eerste resultaten terren een effectiviteit van 100 mg sildenafil in 50% van de 
patienten aan. Patienten die werden behandeld met nitraten in verband met een 
cardiovasculaire aandoening waren geexc1udeerd voor de studie. Voor deze categorie mannen 
zou autoinjectietherapie, ofvacuiimpomp of in het laatste geval een erectieprothese een goed 
altematief1.."UIlIlen zijn als behandeling van ED als gevolg van radiatieschade. 
Naar ons idee dienen patienten die behandeld moeten gaan worden voor hun 
prostaatcarcinoom goede voorlichting krijgen over de mogelijke consequenties van de 
radiotherapie op hun seksuele leven en hun seksueel functioneren, en tevens over de 
mogelijke ejaculatiestoomissen. Patienten dienen op dat moment ook volledig geihfonneerd 
te worden over de verscbillende behandelingsopties voor erectiestoomissen, indien die 
zouden gaan optreden. 
Seks, is het relevant bij kankerpatienten? Het antwoord komt van een 71 jarige man die, na 
4 jaar lang onbevredigende seksuele gemeenschap als gevolg van radiotherapie v~~r zijn 
prostaatcarcinoom, sildenafil (Viagra®) gebruih.-te: "'s morgens rond 7 UUT heb ik een pi! 
ingenomen, om 8.15 uur ben ik begonnen met voorspel, met redelijk succes. Bij het 
binnendringen Vlist ik het meteen ... dit wordt als vanouds, na een aantal minuten, kreeg ik een 
erectie, die was zoals weleer, een waardevolle belevingJ" (brief van een patient). 
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LEITER TO TIlE EDITORS 
Visual sexual stimulation and penile vibration 
ill screening men with erectile dysfunction 
L. mCRoeo MD* AND A. K. SLOB PhDt 
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'Department of Urology, University Hospital 'Dijkzigt', and tDepartment 
of Endocrinology and Reproduction. Faculty of Medicine and Health Sciences, 
Erasmus University Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands. 
With great interest we read the December 1993 issue of this journal, an NIH 
consensus statement on impotence and comments and suggestions of about 38 
experts in the field from all over the world. 
We thoroughly appreciated the attempts of the editors of this journal. At the same 
time we were somewhat disappointed by the organizers of the NIH congress that 
apparently an important aspect in the process 'of differential diagnosis of men with 
erectile problems was totally neglected: the use of visual sexual stimulation (VSS). 
Only Morales & Heaton
' 
mentioned it and were somewhat reluctant to really 
advocate this method because of their inability to satisfactorily deal with negative 
results. In an earlier paper they have discussed the use of VSS as a possible 
alternative to NPT'. During the past 15 to 20 years various scientists and clinicians 
have proposed and discussed the use ofVSS, with Or without Vlbrotactile stimulation 
(VIB), eg Bancrofi3, Rosen & Leiblum', Wagner and co-workers5-7. 
In our psychophysiology laboratory we have used VSS routinely for many years 
in the evaluation of more than 550 men with erectile difficulties. In our first paper' 
we reported on the usefulness of an erectiometer for NPT measurements and VSS 
penile response measurements. The erectiometer measures increase in penile 
circumference as well as rigidity of the erection. In a follOW-Up study' we found 
that a positive VSS response and the occurrence of nocturnal erections were of 
relatively high prognostic significance with respect to treatment outcome. In that 
study we suggested that the positive outcome itself is facilitated by the experience 
of a penile response during VSS. Over the years we have optimized our VSS 
methodology by administering concomitant vibrotactile stimulation (VIB) to the 
underside of the tip of the penisl ()"12. It appeared that the enhancing effect of the 
combined stimulation on objective and subjective penile response was greater when 
VIB followed VSS than when it preceded it, a finding which was recently also 
reported by Janssen et alD. To the patient, we always reinforce the penile response 
poSitively: it shows that nothing serious is wrong, that the genital apparatus is 
capable of responding sexually. When no response occurs, we are very keen to 
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reassure the man and explain that such a response has no dio.gnostic significJlnce! We 
emphasize that there are many psychological reasons why a man does not react in 
the laboratory: the film is not sexually stimulatin~ the man could be afraid to lose 
control, the man could be too tense, etc. When no response occurs, we combine 
VSS and VIB with an intracavernous injection (10) of a vasoactive substance. This 
appears to be very successful. Of the last 74 consecutive men treated this way, 58 
(78%) showed a full or almost full erection (usually including a swollen phallus, 
indicating partial psychogenic erection activity). It is worth mentioning that Virag 
and his collaborators routinely used the combination of a low dose 10 with VSS 
when screening men with erectile difficulties". 
Currently, we are pleased with our investigative procedures. They are not very 
invasive, they provide information relevant both to the doctor and to the patient: 
a positive penile response to a sexual stimulus proves that the neurovascular 
mechanism is intact and that the man is potentially sexually potent. Quite frequently, 
the positive response has a positive, therapeutic effect on the patient. Similar findings 
were recently published by Janssen and collaborators13• 
A remark about age: in our process of differential diagnosis all men are exposed 
to VSS and VIB. Although Buvat and co-workers1S have suggested that many men 
of over 50 do not respond to VSS, we have obtained different results. A recent 
unpublished analysis of 406 consecutive pa,tients with ED in the years 1991 through 
1993 revealed that many older men showed a good penile response to VSS. Men 
under 40 years of age responded better than men over 40 years; between 40 and 
80 years men did not differ in their VSS response. The addition of VIB to the VSS 
significantly increased penile response with apprOximately 30% in men of all ages. 
Finally, we would like to repeat a suggestion we made earlier'6. In screening men 
with erectile dysfunction it is important to carry out diagnostic tests (VIB, 10) in 
a sexually positive atmosphere (ie a quiet private room, provided with sexually 
stimulating materials: video or magazine) to reduce the occurrence of false-negative 
results. When such a goal cannot be reached in a urology clinic, close collaboration 
with a psychophysiology lab should be initiated. 
We hope that this letter will invite many colleagues to start using VSS plus VIB, 
with or without la, early in the screening process of men with erectile difficulties. 
It is stimulating to discover how many men with erectile difficulties are still potentially 
able to function sexually. Although the diagnosis reads 'psychogenic', marty 
relatively simple artd effective treatments are available nowadays which can be used, 
in marty cases only temporarily because the problems disappear: vaC\l-pump, 
intracavernous self-injections, elastic bartd around base of penis, yohimbine. Ideally 
these treatments coincide with simple sexual counselling artd positive reinforcement 
by the doctor. 
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